Page last updated: 2024-11-11

fluvoxamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5361192
CHEMBL ID1314286
CHEBI ID93274
SCHEMBL ID178609
MeSH IDM0025397
PubMed CID5324346
CHEMBL ID814
CHEBI ID5138
SCHEMBL ID33983
MeSH IDM0025397

Synonyms (113)

Synonym
BRD-K72676686-103-01-8
c15h21f3n2o2
NCGC00021870-02
NCGC00015431-01
cas-61718-82-9
tocris-1033
lopac-f-2802
NCGC00015431-02
NCGC00018193-01
2-[(z)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
NCGC00018193-03
NCGC00018193-02
89035-92-7
fluvoxamine, (z)-
4e72ph61hl ,
unii-4e72ph61hl
AKOS015891022
(z) fluvoxamine
fluvoxamine maleate impurity b [ep impurity]
fluvoxamine maleate impurity, z-isomer- [usp impurity]
2-((((1z)-5-methoxy-1-(4-(trifluoromethyl)phenyl)pentylidene)amino)oxy)ethanamine
1-pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, o-(2-aminoethyl)oxime, (1z)-
917096-37-8
(z)-5-methoxy-1-[4-(triflurormethyl)phenyl]-1-pentanone o-(2-aminoethyl)oxime
BRD-K31534764-050-01-7
gtpl7189
SCHEMBL178609
CHEMBL1314286
DTXSID60237496
CHEBI:93274
Q409236
F84984
(z)-5-methoxy-1-[4-(triflurormethyl)phenyl]-1-pentanone o-(2-aminoethyl)oxime maleate
1-pentanone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-, o-(2-aminoethyl)oxime, (1e)-
(z)-5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one o-(2-aminoethyl) oxime
ps22 - fluvoxamine
1-pentanone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-, o-(2-aminoethyl)oxime, (1e)-; 1-pentanone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-, o-(2-aminoethyl)oxime, (e)-; fluvoxamine
BIDD:GT0609
AC-1679
BRD-K53517854-050-03-2
du-23000
fluvoxamina
fluvoxaminum
CHEBI:5138 ,
(1e)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one o-(2-aminoethyl)oxime
1-pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, o-(2-aminoethyl)oxime, (e)-
fluvoxamina [inn-spanish]
fluvoxamine [inn:ban]
fluvoxaminum [inn-latin]
LOPAC0_000495
PRESTWICK2_000995
PRESTWICK3_000995
BSPBIO_001089
AB00514702
fluvoxamine
54739-18-3
C07571
DB00176
BPBIO1_001199
NCGC00021870-05
NCGC00021870-04
NCGC00018193-07
CHEMBL814 ,
n06ab08
fluvoxamine (inn)
D07984
2-[(e)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
bdbm50028091
NCGC00018193-08
NCGC00018193-04
NCGC00018193-05
A830353
fvx ,
tox21_110837
dtxcid0024002
dtxsid2044002 ,
cas-54739-18-3
CCG-204586
(e)-5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one o-(2-aminoethyl) oxime
AKOS016003882
o4l1xpo44w ,
unii-o4l1xpo44w
u-23000
1-pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, o-(2-aminoethyl)oxime, (1e)-
fluvoxamine [who-dd]
5-methoxy-4'-(trifluoromethyl)valerophenone (e)-o-(2-aminoethyl)oxime
fluvoxamine [vandf]
fluvoxamine [inn]
fluvoxamine [mi]
HY-B0103
CS-1840
SCHEMBL33983
NCGC00018193-11
tox21_110837_1
(e)-5-methoxy-4'-(trifluormethyl)valerophenon-o-(2-aminoethyl)oxim
AB00513735_05
AB00513735_06
(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine
2-[({(1e)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine
(e)-5-methoxy-1-(4-(trifluoromethyl)phenyl)-pentan-1-one o-(2-aminoethyl) oxime
AS-15332
SDCCGSBI-0050479.P002
NCGC00018193-21
Q27259474
1-pentanone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-,o-(2-aminoethyl)oxime, (1e)-
(e)-5-(methoxy-d3)-1-[4-(triflurormethyl)phenyl]-1-pentanone o-(2-aminoethyl)oxime
EN300-1709091
(e)-(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine
fluvoxaminum (inn-latin)
o-(2-aminoethyl)-n-((1e)-5-methoxy-1-(4-(trifluoromethyl)phenyl)pentylidene)hydroxylamine
(1e)-5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one o-(2-aminoethyl)oxime
fluvoxamina (inn-spanish)
2-(((e)-(5-methoxy-1-(4-(trifluoromethyl)phenyl)pentylidene)amino)oxy)ethan-1-amine

Research Excerpts

Overview

Fluvoxamine (FVX) is an antidepressant proposed to its immunomodulatory effects in preventing deterioration in mild and moderate COVID-19. Fluvoxamine is a selective serotonin reuptake inhibitor, with a half-life of about 30 hours. It is commonly prescribed in the treatment of depression and obsessive and compulsive disorders.

ExcerptReferenceRelevance
"Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that is a strong sigma-1 receptor agonist, and this may effectively reduce cytokine production, preventing clinical deterioration."( Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
Boulware, DR; Facente, SN; Klausner, JD; Lenze, EJ; Reiersen, AM, 2021
)
2.79
"Fluvoxamine is a serotonin selective reuptake inhibitor (SSRI) and has been reported to have the anti-inflammatory properties."( Fluvoxamine Confers Neuroprotection via Inhibiting Infiltration of Peripheral Leukocytes and M1 Polarization of Microglia/Macrophages in a Mouse Model of Traumatic Brain Injury.
Chai, Y; Chen, F; Chen, X; Li, F; Li, Y; Liu, L; Mi, L; Shi, M; Yang, W; Zhang, J; Zhou, Y, 2022
)
2.89
"Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that has been approved for the treatment of depression, obsessive-compulsive disorder, and a variety of anxiety disorders; it is available as an oral preparation. "( Fluvoxamine for the treatment of COVID-19.
Abu-Taha, A; Lehane, C; Maun, A; Mikolajewska, A; Monsef, I; Nyirenda, JL; Schmucker, C; Sofroniou, M; Stegemann, M; Toews, I, 2022
)
3.61
"Fluvoxamine is a selective serotonin reuptake inhibitor commonly used for various types of depression. "( Pharmacokinetics and bioequivalence studies of fluvoxamine maleate tablets in healthy Chinese subjects.
Deng, DC; He, Y; Hu, HT; Huang, XH; Li, MQ; Ren, D; She, DP; Su, L; Wu, JL; Zhang, YH, 2023
)
2.61
"Fluvoxamine (FVX) is an antidepressant proposed to its immunomodulatory effects in preventing deterioration in mild and moderate COVID-19."( Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study).
Buttakosa, M; Jarrusrojwuttikul, T; Mahanonda, N; Nimmol, T; Silapant, P; Siripongboonsitti, T; Sornsamdang, G; Tawinprai, K; Ungtrakul, T, 2023
)
2.63
"Fluvoxamine is a selective serotonin reuptake inhibitor, with a half-life of about 30 hours, that is commonly prescribed in the treatment of depression and obsessive and compulsive disorders. "( Distribution of Fluvoxamine and Identification of the Main Metabolite in a Fatal Intoxication.
Freni, F; Moretti, M; Morini, L; Osculati, AMM; Quaiotti, J; Tajana, L; Vignali, C, 2021
)
2.41
"Fluvoxamine is a selective serotonin reuptake inhibitor and a potent SIGMAR1 agonist."( Effect of Fluvoxamine on Amyloid-β Peptide Generation and Memory.
Dobson-Stone, C; Fu, Y; Garner, B; Hallupp, M; Hsiao, JT; Karl, T; Kim, WS; Kwok, JBJ; Schofield, PR; Shang, K, 2018
)
1.6
"Fluvoxamine is a selective serotonin reuptake inhibitor that has been considered relatively safe in overdose. "( A fluvoxamine-related fatality: Case report with postmortem concentrations.
Cantrell, L; McIntyre, IM; Morhaime, J; Otter, J, 2019
)
2.68
"Fluvoxamine (Flv) is a selective serotonin reuptake inhibitor (SSRI) with a high affinity for Sig-1R."( Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor.
Chevallier, N; Hara, H; Imaizumi, K; Kanayama, D; Kitasyoji, A; Kudo, T; Marchal, S; Maurice, T; Morihara, T; Okochi, M; Omi, T; Sakagami, Y; Sato, M; Tagami, S; Takeda, M; Tanimukai, H; Yanagida, K, 2014
)
2.57
"Fluvoxamine is a potent CYP1A2 inhibitor and may increase the ratio of clozapine to its primary metabolite N-desmethylclozapine (NDMC)."( The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review.
Nielsen, J; Polcwiartek, C, 2016
)
1.43
"Fluvoxamine is a selective serotonin reuptake inhibitor widely used in the treatment of depression and other psychiatric diseases. "( Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients.
Hashimoto, H; Kagawa, Y; Katoh, Y; Kawai, M; Kawakami, J; Mori, N; Namiki, N; Takei, N; Uchida, S; Yamada, S, 2010
)
2.04
"Fluvoxamine is a selective serotonin reuptake inhibitor antidepressant."( CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics.
Fukui, N; Inoue, Y; Ono, S; Ozdemir, V; Someya, T; Sugai, T; Suzuki, Y; Watanabe, J, 2011
)
1.36
"Fluvoxamine is a viable treatment for prostatodynia. "( A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder.
Ferrier, IN; Grant, JB; Linsley, KR; Rao, NS; Turkington, D; Young, AH, 2002
)
2.04
"Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that is used in the management of depression and obsessive compulsive disorders. "( Status epilepticus following intentional overdose of fluvoxamine: a case report with serum fluvoxamine concentration.
Dargan, PI; Gerrie, D; Greene, SL; Jones, AL; Morgan, PE; Rajalingam, Y; Wood, DM,
)
1.82
"1 Fluvoxamine maleate is a compound from the series of 2-aminoethyloximethers of aralkylketones which possesses marked inhibition effects on 5-hydroxytryptamine (5-HT) uptake by blood platelets and brain synaptosomes. "( Review of the animal pharmacology and pharmacokinetics of fluvoxamine.
Claassen, V, 1983
)
1.23
"Fluvoxamine is a more potent inhibitor of 5-hydroxytryptamine (5-HT) reuptake in some systems, but not in others."( Fluvoxamine and clomipramine in the treatment of cataplexy.
Parkes, JD; Schachter, M, 1980
)
2.43
"1. Fluvoxamine is a potent serotonin re-uptake inhibitor, with little or no noradrenergic or anticholinergic activity. "( Fluvoxamine maleate, a serotonergic antidepressant; a comparison with chlorimipramine.
Block, BA; Coleman, BS, 1982
)
2.33
"Fluvoxamine is an antidepressant drug introduced into the clinic in 1986. "( High performance liquid chromatography with ultraviolet detection used for laboratory routine determination of fluvoxamine in human plasma.
Belmadani, A; Bonini, M; Combourieu, I; Creppy, EE, 1995
)
1.95
"Fluvoxamine is a selective inhibitor of serotonin reuptake that is widely used in the management of depression. "( Clinical pharmacokinetics of fluvoxamine.
Gatti, G; Perucca, E; Spina, E, 1994
)
2.02
"Fluvoxamine was shown to be a safe drug and no unexpected or previously undetected drug-related events were encountered."( Prescription-event monitoring of 10,401 patients treated with fluvoxamine.
Edwards, JG; Inman, WH; Pearce, GL; Wilton, L, 1994
)
1.25
"Fluvoxamine appears to be a safe and effective treatment for bulimia nervosa."( Open trial of fluvoxamine in the treatment of bulimia nervosa.
Ayuso-Gutierrez, JL; Ayuso-Mateos, JL; Palazón, M, 1994
)
1.37
"Fluvoxamine was found to be an effective and well-tolerated treatment for panic using clinician- and patient-rated variables."( A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder.
Black, DW; Bowers, W; Gabel, J; Wesner, R, 1993
)
1.35
"Fluvoxamine is a new antidepressant and selectively inhibits serotonin reuptake (SSRI). "( Fluvoxamine is a potent inhibitor of cytochrome P4501A2.
Brøsen, K; Loft, S; Poulsen, HE; Rasmussen, BB; Skjelbo, E, 1993
)
3.17
"Fluvoxamine is a recently approved serotonin selective reuptake inhibitor (SSRI) with few side effect profiles. "( Serotonin syndrome and fluvoxamine: a case study.
Bastani, AJ; Bastani, JB; Troester, MM, 1996
)
2.05
"Fluvoxamine is a selective serotonin reuptake inhibitor used widely in the treatment of depression and other psychiatric diseases, but little is known about the specific isozymes involved in its metabolism. "( Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.
Alm, C; Bertilsson, L; Carrillo, JA; Dahl, ML; Rodríguez, I; Svensson, JO, 1996
)
2.09
"Fluvoxamine is a potent inhibitor of CYP1A2, and there is potential for interaction with drugs that are metabolised by this isoenzyme."( Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2.
Brøsen, K, 1995
)
1.01
"Fluvoxamine is a potent inhibitor of CYP1A2, and period B was included as a positive control."( Griseofulvin and fluvoxamine interactions with the metabolism of theophylline.
Brøsen, K; Gaist, D; Jeppesen, U; Rasmussen, BB, 1997
)
1.36
"Fluvoxamine is a specific serotonin reuptake inhibitor. "( Serotonin and human information processing: fluvoxamine can improve reaction time performance.
Blin, O; Hasbroucq, T; Possamai, CA; Rihet, P, 1997
)
2
"Fluvoxamine is an effective inhibitor of CYP2C19."( Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide.
Brøsen, K; Jeppesen, U; Rasmussen, BB, 1997
)
3.18
"Fluvoxamine is a selective serotonin (5-HT) reuptake inhibitor (SSRI) with a broad spectrum of behavioral and therapeutic effects, e.g. "( Patterns of c-fos expression induced by fluvoxamine are different after acute vs. chronic oral administration.
Coolen, LM; Joosten, H; Mos, J; Olivier, B; Ronken, E; Spooren, WJ; van Oorschot, R; Veening, JG, 1998
)
2.01
"Fluvoxamine is a fairly potent inhibitor of CYP2C19 and it has the potential for causing drug-drug interactions with substrates for CYP2C19 such as imipramine, clomipramine, amitriptyline and diazepam. "( Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.
Brøsen, K; Nielsen, TL; Rasmussen, BB,
)
3.02
"Fluvoxamine (FLUVOX) is an inhibitor of the cytochrome P450 isoenzyme 1 A2 and thereby inhibits clozapine (CLOZ) metabolism. "( Coadministration of clozapine and fluvoxamine in psychotic patients--clinical experience.
Deuschle, M; Härtter, S; Heese, C; Heuser, I; Hiemke, C; Lammers, CH; Weigmann, H, 1999
)
2.03
"Fluvoxamine was found to be a very potent inhibitor of tacrine metabolism. "( Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo.
Brøsen, K; Hansen, LL; Larsen, JT; Spigset, O, 1999
)
3.19
"Fluvoxamine is a potent and selective serotonin reuptake inhibitor (SSRI) that has little or no effect on other monoamine reuptake mechanisms. "( Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
Figgitt, DP; McClellan, KJ, 2000
)
3.19
"Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo."( Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
Brøsen, K; Enggaard, TP; Hansen, LL; Klitgaard, NA; Madsen, H, 2001
)
3.2
"Fluvoxamine is an effective treatment for children and adolescents with social phobia, separation anxiety disorder, or generalized anxiety disorder."( Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group.
, 2001
)
3.2
"Fluvoxamine is a potent anti-panic agent with a relatively rapid onset of action."( Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients.
Asnis, GM; Black, D; Desagani, K; Goddard, AW; Hameedi, FA; Jameel, M; Potkin, SG; Woods, SW, 2001
)
2.47
"Fluvoxamine, an SSRI, is a potent inhibitors for CYP1A2 and CYP2C19, moderate for CYP3A4 and weak for CYP 2D6."( [Pharmacokinetics and drug interactions of antidepressive agents].
Ohtani, H; Sawada, Y, 2001
)
1.03
"Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which may be used for the management of anxiety disorders in children and adolescents. "( Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents.
Cheer, SM; Figgitt, DP, 2001
)
3.2
"Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which may be used for the management of anxiety disorders in children and adolescents. "( Spotlight on fluvoxamine in anxiety disorders in children and adolescents.
Cheer, SM; Figgitt, DP, 2002
)
2.13
"Fluvoxamine is a potent and specific 5-HT reuptake inhibitor which has been available since 1983 and is estimated to have been given to two and a half million patients since it was first investigated in patients with depression in the late 1970s. "( A review of fluvoxamine and its uses in depression.
Burton, SW, 1991
)
2.1
"Fluvoxamine appears to be a valuable alternative to the tricyclic antidepressants, and has a high margin of safety in overdose."( Overdose and safety with fluvoxamine.
Henry, JA, 1991
)
1.31
"Fluvoxamine was found to be a potent anti-panic agent."( Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline.
Den Boer, JA; Westenberg, HG, 1988
)
1.21
"Fluvoxamine is an antidepressant which, like fenfluramine, inhibits serotonin re-uptake within the brain."( Placebo controlled double-blind trial of fluvoxamine maleate in the obese.
Abell, CA; Farquhar, DL; Galloway, SM; Munro, JF; Philip, AE; Steven, F, 1986
)
1.26
"Fluvoxamine is a new antidepressant which potently and specifically inhibits neuronal reuptake of serotonin. "( Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
Benfield, P; Ward, A, 1986
)
3.16
"Fluvoxamine is a real antidepressant with a marked effect on mood."( A Belgian multicentre study of fluvoxamine in depressive outpatients.
Ansseau, M; Bartholome, F; Brasseur, R; Mesotten, F; Uytdenhoef, P; Van Moffaert, M,
)
1.14

Effects

Fluvoxamine has a rapid action with lifting of the mood often within 4-7 days, in a dosage range from 150 to 200 mg/day. The drug has an extensive elimination half-life of 17-22 hours after a single dose, which increases with multiple dosing by 30-50%.

Fluvoxamine has been approved in about 80 countries as the indication to "depression" since 1983. It has shown short term efficacy in the treatment of OCD, panic disorder, social phobia, PTSD and in a range of obsessive-compulsive spectrum disorders.

ExcerptReferenceRelevance
"Fluvoxamine has a similar spectrum of adverse effects as compared to other selective serotonin reuptake inhibitors. "( Fluvoxamine induced oculogyric dystonia and manic switch in a patient with obsessive compulsive disorder.
Das, B; Garg, S; Tikka, SK,
)
3.02
"Fluvoxamine has an extensive elimination half-life of 17-22 hours after a single dose, which increases with multiple dosing by 30-50%."( Fluvoxamine interaction with warfarin.
Elliott, ES; Limke, KK; Shelton, AR, 2002
)
2.48
"Fluvoxamine has a rapid action with lifting of the mood often within 4-7 days, in a dosage range from 150 to 200 mg/day."( Long-term study of fluvoxamine: a new rapid-acting antidepressant.
Denber, HC; Feldmann, HS, 1982
)
1.31
"Fluvoxamine has a response rate similar to that of the currently most efficacious treatments for delusional depression, including antidepressants plus antipsychotics and ECT."( Fluvoxamine alone in the treatment of delusional depression.
Bellini, L; Gasperini, M; Gatti, F; Perez, J; Smeraldi, E; Zanardi, R, 1996
)
3.18
"Fluvoxamine has a rapid onset of action and is well tolerated and efficacious for the short-term treatment of pediatric OCD."( Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
Claghorn, JL; Gaffney, G; Greist, JH; Holland, D; McConville, BJ; Pigott, T; Reeve, EA; Riddle, MA; Walkup, JT; Yang, HM; Yaryura-Tobias, JA, 2001
)
3.2
"Fluvoxamine has certain advantages over the other SSRIs in the treatment of patients with a depression and comorbid AUD."( [Dual diagnosis: depression and alcohol use disorder].
Egorov, AY; Krupitsky, EM; Mendelevich, VD; Rybakova, KV; Sivolap, YP; Usov, GM; Vinnikova, MA, 2021
)
1.34
"Fluvoxamine has the most favorable safety profile."( [Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study].
Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA, 2021
)
2.25
"Fluvoxamine has not been approved for the treatment of infections, but has been used in the early treatment of people with mild to moderate COVID-19."( Fluvoxamine for the treatment of COVID-19.
Abu-Taha, A; Lehane, C; Maun, A; Mikolajewska, A; Monsef, I; Nyirenda, JL; Schmucker, C; Sofroniou, M; Stegemann, M; Toews, I, 2022
)
2.89
"Fluvoxamine (FVX) has been proposed as a potential treatment for severe COVID-19 by the σ-1 receptor agonist, which can reduce cytokine production. "( The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial).
Mahanonda, N; Payoong, P; Siripongboonsitti, T; Tawinprai, K, 2023
)
2.64
"Fluvoxamine has procognitive effects, stabilizes remission and improves social adaptation of the patients."( [Procognitive effects of fluvoxamine: preliminary data].
Bobrov, AE; Krasnoslobodtseva, LA; Mutnykh, EM,
)
1.88
"Fluvoxamine has a similar spectrum of adverse effects as compared to other selective serotonin reuptake inhibitors. "( Fluvoxamine induced oculogyric dystonia and manic switch in a patient with obsessive compulsive disorder.
Das, B; Garg, S; Tikka, SK,
)
3.02
"Fluvoxamine has demonstrated efficacy in both these conditions and has recently been marketed in a controlled-release (CR) formulation in the United States for treatement of OCD and SAD."( Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia.
Owen, RT, 2008
)
1.4
"Fluvoxamine has the potential to inhibit CYP1A2, CYP2C9, CYP2C19, and CYP3A4 to a significant degree."( Fluvoxamine interaction with warfarin.
Elliott, ES; Limke, KK; Shelton, AR, 2002
)
2.48
"Fluvoxamine CR has been reported effective in the short-term (12-wk) treatment of generalized social anxiety disorder (social phobia). "( Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial.
Barbato, LM; Li, D; Stein, DJ; Westenberg, HG; Yang, H, 2003
)
3.2
"3 Fluvoxamine has no effects on the heart except for a statistically (but not clinically) significant slowing of the heart rate."( Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine.
Roos, JC, 1983
)
1.04
"Fluvoxamine has a rapid action with lifting of the mood often within 4-7 days, in a dosage range from 150 to 200 mg/day."( Long-term study of fluvoxamine: a new rapid-acting antidepressant.
Denber, HC; Feldmann, HS, 1982
)
1.31
"Fluvoxamine has also been shown to reduce general and phobic anxiety in social phobia patients."( Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine.
De Leeuw, AS; den Boer, JA; van Vliet, IM; Westenberg, HG, 1995
)
1.22
"Fluvoxamine has been described as a specific uptake inhibitor for serotonin uptake and we therefore supposed that an iodinated derivative of this compound would be a suitable tracer for this purpose."( Synthesis of 4'-iodo-5-methoxy-valerophenone O-(2-aminoethyl)oxime as an agent for exploration of serotoninergic transporter.
Besnard, JC; Branger, C; Caillet, M; Chalon, S; Dognon, AM; Frangin, Y; Garreau, L; Guilloteau, D; Ombetta-Goka, JE, 1995
)
1.01
"Fluvoxamine has a response rate similar to that of the currently most efficacious treatments for delusional depression, including antidepressants plus antipsychotics and ECT."( Fluvoxamine alone in the treatment of delusional depression.
Bellini, L; Gasperini, M; Gatti, F; Perez, J; Smeraldi, E; Zanardi, R, 1996
)
3.18
"Fluvoxamine has prominent affinity for the CYP12 isozyme, lesser affinity for the CYP3A4 and CYP2C isozymes, and minimal affinity for CYP2D6."( Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane, CL; Gill, HS, 1997
)
1.31
"Fluvoxamine has been shown to increase methadone blood levels."( A therapeutic use of the methadone fluvoxamine drug interaction.
DeMaria, PA; Serota, RD, 1999
)
1.3
"Fluvoxamine has been approved in about 80 countries as the indication to "depression" since 1983."( [Pharmacological and clinical aspects of fluvoxamine (Depromel), the first selective serotonin reuptake inhibitor approved for clinical use employed in Japan].
Hachisu, M; Ichimaru, Y, 2000
)
1.29
"Fluvoxamine has demonstrated short term efficacy in the treatment of OCD, panic disorder, social phobia, PTSD and in a range of obsessive-compulsive spectrum disorders. "( Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
Figgitt, DP; McClellan, KJ, 2000
)
3.19
"Fluvoxamine has a rapid onset of action and is well tolerated and efficacious for the short-term treatment of pediatric OCD."( Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
Claghorn, JL; Gaffney, G; Greist, JH; Holland, D; McConville, BJ; Pigott, T; Reeve, EA; Riddle, MA; Walkup, JT; Yang, HM; Yaryura-Tobias, JA, 2001
)
3.2
"Fluvoxamine has been widely used in Japan for approximately 1 year."( Restlessness related to SSRI withdrawal.
Hirose, S, 2001
)
1.03
"Fluvoxamine has been found to be superior to placebo and equivalent to imipramine, clomipramine, desipramine, mianserin, and maprotiline in the treatment of depression."( Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.
Grimsley, SR; Jann, MW, 1992
)
1.3

Actions

Fluvoxamine did not increase the incidence of ventricular arrhythmias induced by programmed electrical ventricular stimulation. Fluvoxamine inhibited the increase in [Ca(2+)]m induced by changes in the Ca(2+) content of the perfusate in perfused preparations of mitochondria.

ExcerptReferenceRelevance
"Fluvoxamine inhibited the increase in [Ca(2+)]m induced by changes in the Ca(2+) content of the perfusate in perfused preparations of mitochondria, which was similar to the results obtained with the mitochondrial permeability transition pore (MPTP) opener atractyroside."( Protective effects of fluvoxamine against ischemia/reperfusion injury in isolated, perfused guinea-pig hearts.
Hotta, Y; Mitsui-Saitoh, K; Mizutani, H; Muto, T; Nonogaki, T; Ohashi, A; Sakai, J; Sugimoto, Y; Usuda, H; Yamamura, A; Yoshida, K, 2014
)
1.44
"Fluvoxamine did not increase the incidence of ventricular arrhythmias induced by programmed electrical ventricular stimulation (n = 8)."( Comparative electrophysiological effects of the antidepressants fluvoxamine and amitriptyline in the canine heart after myocardial infarction.
Hashimoto, H; Ikeda, Y; Nakashima, M; Nishimoto, M; Shimazu, Y; Umemura, K, 1996
)
1.25
"Fluvoxamine displays nonlinear steady-state pharmacokinetics over the therapeutic dose range, with disproportionally higher plasma concentrations with higher dosages."( Overview of the pharmacokinetics of fluvoxamine.
van Harten, J, 1995
)
1.29

Treatment

Fluvoxamine treatment promoted microglial/macrophage phenotypic transformation from pro-inflammatory to anti-inflammatory. We did not identify any completed studies of inpatients. Fluvoxamine is failed to demonstrate effectiveness in preventing deterioration in mild to moderate COVID-19.

ExcerptReferenceRelevance
"Fluvoxamine treatment in addition to the standard therapy in hospitalised ICU COVID-19 patients could have a positive impact on patient survival. "( Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls.
Calusic, M; Jurkovic, I; Kovac, N; Likic, R; Luksa, L; Marcec, R; Mihaljevic, S, 2022
)
2.47
"Fluvoxamine treatment promoted microglial/macrophage phenotypic transformation from pro-inflammatory M1-phenotype to anti-inflammatory M2-phenotype in"( Fluvoxamine Confers Neuroprotection via Inhibiting Infiltration of Peripheral Leukocytes and M1 Polarization of Microglia/Macrophages in a Mouse Model of Traumatic Brain Injury.
Chai, Y; Chen, F; Chen, X; Li, F; Li, Y; Liu, L; Mi, L; Shi, M; Yang, W; Zhang, J; Zhou, Y, 2022
)
2.89
"Fluvoxamine for the treatment of COVID-19 in inpatients We did not identify any completed studies of inpatients."( Fluvoxamine for the treatment of COVID-19.
Abu-Taha, A; Lehane, C; Maun, A; Mikolajewska, A; Monsef, I; Nyirenda, JL; Schmucker, C; Sofroniou, M; Stegemann, M; Toews, I, 2022
)
2.89
"Fluvoxamine treatment is failed to demonstrate effectiveness in preventing deterioration in mild to moderate COVID-19 and may lead to a higher incidence of pneumonia, hospitalization, and oxygen supplementation, necessitating careful consideration before prescribing the drug for COVID-19."( The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial).
Mahanonda, N; Payoong, P; Siripongboonsitti, T; Tawinprai, K, 2023
)
2.64
"Fluvoxamine pretreatment increased Cmax and AUC0-∞  of nebivolol (Cmax: 1.67 ± 0.690  vs 2.20 ± 0.970  ng/mL; AUC0-∞: 12.1 ± 11.0  vs 19.3 ± 19.5  ng*h/mL ) and of its active metabolite (Cmax: 0.680  ± 0.220  vs 0.960 ± 0.290  ng/mL; AUC0-∞: 17.6 ±20.1  vs 25.5 ± 29.9  ng*h/mL). "( Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers.
Achim, M; Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Todor, I; Tomuta, I; Vlase, L, 2017
)
2.13
"Fluvoxamine-treated rats showed significantly lower neuropeptide Y (NPY) immunostaining levels in the paraventricular nucleus (PVN) and dorsomedial hypothalamic nucleus (DMH) than untreated controls."( Fluvoxamine inhibits weight gain and food intake in food restricted hyperphagic Wistar rats.
Hosoyamada, M; Kimura, M; Shibasaki, T; Shinozaki, T, 2008
)
2.51
"Fluvoxamine treatment significantly restored PO-induced impaired eNOS and Akt activity in the LV."( Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions.
Bhuiyan, MS; Fukunaga, K; Shioda, N; Tagashira, H, 2010
)
1.37
"Fluvoxamine treatment protects PO-induced cardiac injury via upregulation of Sig-1R and stimulation of Sig-1R-mediated Akt-eNOS signaling in ovariectomized rats."( Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions.
Bhuiyan, MS; Fukunaga, K; Shioda, N; Tagashira, H, 2010
)
1.37
"Fluvoxamine treatment significantly restored TAC-induced impaired Akt and endothelial nitric oxide synthase (eNOS) phosphorylation in the LV."( Sigma1-receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice.
Bhuiyan, S; Fukunaga, K; Hasegawa, H; Kanai, H; Shioda, N; Tagashira, H, 2010
)
1.36
"Fluvoxamine treatment also significantly restored pressure overload-induced impaired Akt phosphorylation and stimulated eNOS protein expression as well as Akt-mediated eNOS phosphorylation (Ser1177)."( Sigma-1 receptor stimulation with fluvoxamine activates Akt-eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding.
Bhuiyan, MS; Fukunaga, K; Tagashira, H, 2011
)
1.37
"Fluvoxamine treatment significantly restored TAC-induced impaired Akt and eNOS phosphorylation in LV."( [Cardioprotective effect of fluvoxamine, sigma-1 receptor high affinity agonist].
Fukunaga, K; Tagashira, H, 2012
)
1.39
"The fluvoxamine-treated group had significantly lower (p = .02) final scores on the General Health Questionnaire, indicating an overall benefit from pain relief."( A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder.
Ferrier, IN; Grant, JB; Linsley, KR; Rao, NS; Turkington, D; Young, AH, 2002
)
1.08
"Fluvoxamine is a viable treatment for prostatodynia. "( A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder.
Ferrier, IN; Grant, JB; Linsley, KR; Rao, NS; Turkington, D; Young, AH, 2002
)
2.04
"Fluvoxamine treatment increased C(max) of omeprazole by 3.7-fold (95%CI, 2.4, 5.0-fold, P < 0.01) and 2.0-fold (1.4, 2.6-fold, P < 0.01), AUC(0,8 h) by 6.0-fold (3.3, 8.7-fold, P < 0.001) and 2.4-fold (1.7, 3.2-fold, P < 0.01), AUC(0, infinity ) by 6.2-fold (3.0, 9.3-fold, P < 0.01) and 2.5-fold (1.6, 3.4-fold, P < 0.001) and prolonged t((1/2)) by 2.6-fold (1.9, 3.4-fold, P < 0.001) and 1.4-fold (1.02, 1.7-fold, P < 0.05), respectively."( Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
Inoue, Y; Kaneko, S; Nakagami, T; Takahata, T; Tateishi, T; Yasui-Furukori, N; Yoshiya, G, 2004
)
1.33
"Fluvoxamine treatment increased AUC(0-infinity) of lansoprazole by 3.8-fold (P < .01) in homozygous EMs and by 2.5-fold (P < .05) in heterozygous EMs, whereas no difference in any pharmacokinetic parameters was found in PMs."( Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Saito, M; Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N, 2004
)
1.43
"Fluvoxamine treatment increased AUC(0,infinity) of rabeprazole and rabeprazole thioether by 2.8-fold (P<0.001) and 5.1-fold (P<0.01) in homozygous EMs, and by 1.7-fold (P<0.01) and 2.6-fold (P<0.01) in heterozygous EMs, and significantly prolonged the elimination half-life of rabeprazole and rabeprazole thioether in homozygous EMs and in heterozygous EMs, whereas no difference in any pharmacokinetic parameters was found in PMs."( Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Shimizu, M; Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N, 2006
)
1.37
"Fluvoxamine treatment was initiated at 50 mg/d, and increased by 50 mg weekly to a maximum of 150 or 300 mg/d."( Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study.
Asakura, S; Koyama, T; Tajima, O, 2007
)
2.5
"Fluvoxamine treatment significantly improved clinical symptoms and increased [(11)C]Rac binding potential (BP) in the basal ganglia of OCD patients (7.5+/-5.2, 6.9+/-6.9, and 9.9+/-9.3% in dorsal caudate, dorsal putamen, and ventral basal ganglia, respectively; p<0.01) to values closer to those observed in the group of normal subjects."( Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naïve patients.
Bellodi, L; Bonaldi, L; Carpinelli, A; Fazio, F; Gobbo, C; Henin, M; Locatelli, M; Moresco, RM; Panzacchi, A; Perani, D; Pietra, L, 2007
)
2.5
"Fluvoxamine treatment, on the other hand, produced no clear effect on any measure of noradrenergic function and the antidepressant efficacy of fluvoxamine was unrelated to any noradrenergic variable."( Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients.
Ballenger, JC; Johnson, MR; Kellner, CH; Laird, LK; Lydiard, RB; Morton, WA; Steele, TE,
)
1.26
"Fluvoxamine treatment reduced yohimbine-induced anxiety while placebo treatment had no effect on this variable."( Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder.
Charney, DS; Goddard, AW; Goodman, WK; Heninger, GR; Sholomskas, DE; Woods, SW, 1993
)
1.27
"Fluvoxamine treatment of depression for one year was not associated with any significant effect on the ECG."( Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience.
Hochberg, HM; Houser, VP; Kanter, D, 1995
)
1.97
"Fluvoxamine treatment resulted in a nearly 3-fold increase in plasma buspirone with a similar enhancement of the PRL response."( The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone in normal volunteers.
Anderson, IM; Deakin, JF; Miller, HE, 1996
)
1.33
"Fluvoxamine treatment did not influence plasma and platelet levels of amino acids or trp/LNAAs ratio."( Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment.
Alecci, M; Boscati, L; Bravin, S; Ferrara, A; Invernizzi, G; Mauri, MC; Zamberlan, F, 1998
)
1.24
"Fluvoxamine treatment resulted in gambling abstinence in seven of the 10 patients."( Short-term single-blind fluvoxamine treatment of pathological gambling.
Begaz, T; DeCaria, CM; Grossman, R; Hollander, E; Mari, E; Mosovich, S; Wong, CM, 1998
)
1.33
"Fluvoxamine treatment significantly improved clinical symptoms and modified [(18)F]FESP binding in the frontal and occipital cortex of all of the nine patients who completed the study; in these regions a mean 31% increase in the in vivo [(18)F]FESP binding was found (P < 0.01)."( Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study.
Bonfanti, A; Colombo, C; Del Sole, A; Fazio, F; Galli, L; Gobbo, C; Lucca, A; Lucignani, G; Messa, C; Moresco, RM; Smeraldi, E, 2000
)
1.42
"The fluvoxamine treatment was discontinued, and hypertonic saline was infused."( [Three cases of severe hyponatremia under taking selective serotonin reuptake inhibitor (SSRI)].
Hayashi, H; Inaguma, D; Kanoh, T; Kitagawa, W; Kumon, S; Kurata, K, 2000
)
0.79
"Fluvoxamine treatment resulted in significant improvements in some clinical findings such as eye contact and language use, as tested by behavioral assessment scores consisting of twenty items (p < 0.05)."( [Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder].
Fukuda, T; Ito, M; Sugie, H; Sugie, Y, 2001
)
1.3
"Fluvoxamine treatment led to improvements in PTSD symptoms and all domains of subjective sleep quality."( Fluvoxamine and sleep disturbances in posttraumatic stress disorder.
Best, SR; Lenoci, M; Lipsey, TL; Marmar, CR; Metzler, TJ; Neylan, TC; Schoenfeld, FB; Weiss, DS, 2001
)
2.47
"Fluvoxamine treatment was associated with significant improvement on measures of obsessive-compulsive symptoms, anxiety, and depression."( Fluvoxamine treatment of obsessive-compulsive disorder.
Dar, R; Greist, JH; Jefferson, JW; Perse, TL; Rosenfeld, R, 1987
)
2.44
"Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early diagnosed COVID-19 reduced the need for hospitalisation defined as retention in a COVID-19 emergency setting or transfer to a tertiary hospital."( Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Callegari, ED; de Almeida, APFG; de Figueiredo Neto, AD; de Souza Campos, VH; Dos Santos Moreira-Silva, EA; Dos Santos, CVQ; Ferreira, TS; Forrest, JI; Glushchenko, AV; Guyatt, GH; Harari, O; Lenze, EJ; McKay, P; Milagres, AC; Mills, EJ; Nogueira, AMR; Oliveira, R; Rayner, CR; Reiersen, AM; Reis, G; Ribeiro, LB; Ruton, H; Savassi, LCM; Silva, DCM; Simplicio, MIC; Sprague, S; Thabane, L, 2022
)
1.36
"Treatment with fluvoxamine did not result in alterations in the 24-h pattern of motor activity."( 24-Hour motor activity after treatment with imipramine or fluvoxamine in major depressive disorder.
Bruijn, JA; Passchier, J; Pepplinkhuizen, L; Tulen, JH; Van Den Broek, WW; Volkers, AC, 2002
)
0.9
"Treatment with fluvoxamine CR resulted in statistically and clinically significant improvements in symptoms associated with generalized social anxiety disorder as early as week 4 on the Liebowitz Social Anxiety Scale and the Clinical Global Impression Scale Global Improvement, and at week 6 on the Sheehan Disability Scale, Clinical Global Impression Scale Severity of Illness and the Patient Global Impression of Improvement Scale. "( Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder.
Barbato, LM; Davidson, J; DuPont, R; Li, D; Stallings, L; van der Hoop, RG; Yaryura-Tobias, J, 2004
)
2.12
"Treatment with fluvoxamine (20 mg/kg, i.p.) or paroxetine (10 mg/kg, i.p.) completely inhibited forced exercise-induced flushing of tail skin in ovariectomized mice, and the effect of each was comparable to that of estradiol replacement."( Selective serotonin reuptake inhibitors fluvoxamine and paroxetine restore forced exercise-induced temperature dysregulation in ovariectomized mice.
Egawa, T; Ikeda, M; Kataoka, Y; Koga, A; Shuto, H; Sohda, Y; Tominaga, K; Yamauchi, A, 2008
)
0.95
"Treatment with fluvoxamine (150 mg daily) significantly decreased the sensitivity of PD patients for CCK4 while placebo was without effect."( Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks.
den Boer, JA; Scheepmakers, A; Slaap, B; van Megen, HJ; Westenberg, HG, 1997
)
0.89
"The treatment with fluvoxamine was started at the dose of 25 mg daily."( Alleviation of sleep disturbance and repetitive behavior by a selective serotonin re-uptake inhibitor in a boy with Asperger's syndrome.
Furusho, J; Ichihashi, I; Kumagai, K; Matsuzaki, K; Satoh, H; Yamaguchi, K, 2001
)
0.63
"Pretreatment with fluvoxamine, MK-801, ketamine and the combination of fluvoxamine with either of the NMDA antagonists antagonised shock-induced depression."( Effect of fluvoxamine and N-methyl-D-aspartate receptor antagonists on shock-induced depression in mice.
Bapna, JS; Chandra, D; Chaturvedi, HK, 2001
)
1.04
"Treatment with fluvoxamine resulted in a profound reduction in the number of panic attacks, followed by a decrease in avoidance behavior."( Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin.
Den Boer, JA; Westenberg, HG, 1990
)
0.84

Toxicity

Fluoxetine and fluvoxamine with worst-case 96-h IC10s of 4. Sertraline was the most toxic SSRI tested in single-species growth inhibition assays.

ExcerptReferenceRelevance
" The greatest proportion of adverse experiences occurring, by COSTART body system, affected the digestive system (24."( Review of fluvoxamine safety database.
Essers, H; Gray, TE; Plekkenpol, B; Vlaskamp, H; Wagner, W, 1992
)
0.69
" In conclusion, the study gives further support to the hypothesis that SSRI-RIMA combinations may be safe and well tolerated."( Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy.
Albert, R; Ebert, D; Kaschka, W; May, A; Stosiek, I, 1995
)
0.29
" Safety findings revealed a pharmacological adverse event profile similar to that seen with other serotonin reuptake inhibitors."( Fluvoxamine. A review of its safety profile in world-wide studies.
Gray, TE; Wagner, W; Zaborny, BA, 1994
)
1.73
" In both trials, patients on fluvoxamine complained of a variety of adverse effects, which they often identified as the basis for early termination of treatment."( Adverse effects limit the usefulness of fluvoxamine for the treatment of alcoholism.
Brown, J; Del Boca, F; Korner, P; Kranzler, HR,
)
0.69
"4% of the patients exposed to fluvoxamine did not have any adverse experiences."( Safety database on fluvoxamine: analysis and report.
Essers, H; Gray, TE; Plekkenpol, B; Vlaskamp, H; Wagner, W, 1993
)
0.9
" EEG, ECG, and laboratory parameters and adverse effects reported by the patients, as well as global clinical improvement, were assessed."( Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
Härtter, S; Hiemke, C; Leal, M; Szegedi, A; Wetzel, H, 1996
)
0.56
"To study the adverse drug reaction (ADR) profile of selective serotonin re-uptake inhibitors (SSRI) in Belgium and the Netherlands."( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996
)
0.29
"All adverse reactions of fluoxetine, fluvoxamine, paroxetine and sertraline, reported between the moment of registration of these drugs and January 1st 1995, were assessed for causality."( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996
)
0.57
"At the national monitoring centres of Belgium and of the Netherlands adverse reactions were reported 78 and 537 times, respectively."( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996
)
0.29
" More adverse reactions were reported in the Netherlands than in Belgium."( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996
)
0.29
" We have addressed the question of whether there is a 'serotonin withdrawal syndrome' by analysis of spontaneous reports of suspected adverse drug reactions (ADRs) associated with four SSRIs."( A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.
MacKay, AV; Price, JS; Waller, PC; Wood, SM, 1996
)
0.29
"These results suggest that fluvoxamine is a safe and effective treatment for BDD, including its delusional disorder variant."( Efficacy and safety of fluvoxamine in body dysmorphic disorder.
Dwight, MM; McElroy, SL; Phillips, KA, 1998
)
0.91
"English-language articles identified through MEDLINE (1985 through 1997), and case reports from the American Association of Poison Control Centers (AAPCC) (1987 through 1996) and United States Food and Drug Administration (FDA) adverse event database (through 1997) that describe findings of fatal and nonfatal overdoses involving SSRIs alone or in combination with other ingestants were reviewed."( SSRI safety in overdose.
Barbey, JT; Roose, SP, 1998
)
0.3
" At very high doses (> 75 times the common daily dose), more serious adverse events, including seizures, electrocardiogram (ECG) changes, and decreased consciousness may occur."( SSRI safety in overdose.
Barbey, JT; Roose, SP, 1998
)
0.3
" In another instance heart block and hypotension was noted in association with a diltiazem and atenolol adverse interaction."( Aminophylline reversal of antihypertensive agent toxicity.
Roberge, RJ; Rosetti, JM; Rossetti, ML, 2001
)
0.31
" No adverse effects in the infants were detected by the mother or on clinical examination, and fluvoxamine was not detected in the infants' plasma (limit of detection 2 micrograms/L)."( The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants.
Hackett, LP; Ilett, KF; Kohan, R; Kristensen, JH; Paech, M, 2002
)
0.89
" Post-marketing surveillance provides the opportunity to assess a drug's safety in every day clinical conditions in a much greater patient population than in clinical trials and therefore serves as a useful tool to detect signals for adverse effects with an incidence of less than 1 : 10,000."( Fluvoxamine: safety profile in extensive post-marketing surveillance.
Buchberger, R; Wagner, W, 2002
)
1.76
" To create better treatment, we studied here clinical adverse effects of fluvoxamine and correlated them with genetic polymorphism of two genes, the promoter region of serotonin transporter gene (5-HTTLPR) and serotonin 2A receptor gene (5-HT2AR)."( [Studies on the adverse effects of fluvoxamine treatment in children with autistic disorder: correlation with genetic polymorphism in serotonin related genes].
Fukuda, T; Ito, M; Ohzeki, T; Sugie, H; Sugie, Y, 2003
)
0.83
"Over 12 weeks, fluvoxamine CR treatment was associated with a statistically significant and clinically relevant reduction in OCD severity and was found to be safe and well tolerated."( A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
Barbato, LM; Goodman, WK; Greist, JH; Hollander, E; Koran, LM; Li, D; Ninan, PT; Yang, H, 2003
)
0.89
" The efficacy was assessed using the 17-item Hamilton Rating Scale for Depression (HAM-D), Clinical Global Impression Scale (CGI) severity and improvement scores, while the safety profiles were assessed using the UKU Side Effect Rating Scale at baseline, and on days 7, 14, 28 and 56."( A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
Akimoto, Y; Aoyama, H; Kamijima, K; Koda, R; Mimura, M; Nakagome, K; Otsubo, T; Tanaka, K; Yamada, H, 2005
)
0.57
" As for the safety profiles, the nortriptyline group scored a significantly higher incidence of adverse events such as dysarthria or orthostatic dizziness, as well as increased heart rate."( A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
Akimoto, Y; Aoyama, H; Kamijima, K; Koda, R; Mimura, M; Nakagome, K; Otsubo, T; Tanaka, K; Yamada, H, 2005
)
0.57
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Although SSRIs (and venlafaxine) have similar adverse effects, certain differences are emerging."( Tolerability and safety of fluvoxamine and other antidepressants.
Sandner, C; Westenberg, HG, 2006
)
0.63
" The toxic effect of tacrine on hepatocytes was assayed by the reduction of methyl thiazolyl tetrazolium (MTT) and intracellular glutathione (GSH), as well as by albumin synthesis."( Re-evaluation of tacrine hepatotoxicity using gel entrapped hepatocytes.
Bader, A; Meng, Q; Ru, J; Schmitmeier, S; Shen, C; Zhang, G, 2007
)
0.34
" Clinicians should select antidepressants considering their pharmacologic profiles and avoiding adverse effects."( [Review of pharmacological efficacies and side effects of antidepressants].
Ikenouchi-Sugita, A; Nakamura, J; Yoshimura, R, 2007
)
0.34
" The most common adverse events and pharmacodynamic effects are related to plasma concentrations."( A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients.
Henney, HR; Runyan, JD, 2008
)
0.35
" The case indicates that emerging adverse effects via the pharmacokinetic interaction of these drugs when switching patients from fluvoxamine to paroxetine can occur."( A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R, 2009
)
0.79
"The aim of this study was to examine the prevalence of activation cluster adverse events (AC-AEs) in youths treated with the selective serotonin reuptake inhibitor (SSRI) fluvoxamine for anxiety and the relationship of AC-AEs to SSRI blood levels."( Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.
DosReis, S; Reinblatt, SP; Riddle, MA; Walkup, JT, 2009
)
0.77
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Despite no adverse reports, data on safety for the maternal use of fluvoxamine on breastfed infants are limited."( Gastrointestinal Side Effects in the Baby of a Breastfeeding Woman Treated with Low-Dose Fluvoxamine.
Uguz, F, 2015
)
0.87
" Furthermore, combination therapy provides less adverse effects."( [Optimization of the efficacy and safety of antidepressant therapy in patients of a geriatric psychiatric unit].
Gavrilova, SI; Kalyn, YB; Kornilov, VV; Safarova, TP; Sheshenin, VS; Shipilova, ES; Yakovleva, OB, 2015
)
0.42
" The adverse effects of prolonged oral administration of fluvoxamine on haematology, biochemical parameters and fertility in male rats were evaluated in this study."( Adverse effects of long-term administration of fluvoxamine on haematology, blood biochemistry and fertility in male albino rats: a possible effect of cessation.
Abd El-Aziz, RM; Alam, RT; Galal, AA, 2016
)
0.94
" Some of these patients do not show adequate response to the therapy with fluvoxamine, whereas many of them experience dose-dependent adverse drug reactions."( Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.
Bryun, EA; Bure, IV; Grishina, EA; Kaverina, EV; Klepikov, DA; Ryzhikova, KA; Skryabin, V; Smirnov, V; Sychev, DA; Zastrozhin, MS; Zastrozhina, AK, 2021
)
1.11
" Therapy safety was assessed using the UKU Side-Effect Rating Scale."( Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.
Bryun, EA; Bure, IV; Grishina, EA; Kaverina, EV; Klepikov, DA; Ryzhikova, KA; Skryabin, V; Smirnov, V; Sychev, DA; Zastrozhin, MS; Zastrozhina, AK, 2021
)
0.88
" Therapy safety was assessed using the UKU Side-Effect Rating Scale."( Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder.
Bryun, E; Bure, I; Golovinskii, P; Grishina, E; Koporov, S; Ryzhikova, K; Skryabin, V; Smirnov, V; Sychev, D; Zastrozhin, M; Zastrozhina, A, 2021
)
0.85
" We conducted a meta-analysis to investigate the improvement in mortality or hospitalization rates and adverse events among COVID-19 patients with three new oral antivirals (including molnupiravir, fluvoxamine and Paxlovid)."( Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.
Chen, C; Cheng, Y; Feng, Z; Mao, Q; Tang, J; Wang, C; Wang, M; Wen, W; Wu, Q; Zhang, X; Zhou, M; Zhou, X, 2022
)
1.14
" In addition, the three oral drugs did not increase the occurrence of adverse events, thus exhibiting good overall safety."( Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.
Chen, C; Cheng, Y; Feng, Z; Mao, Q; Tang, J; Wang, C; Wang, M; Wen, W; Wu, Q; Zhang, X; Zhou, M; Zhou, X, 2022
)
0.95
"Tizanidine is primarily metabolized via cytochrome P450 (CYP) 1A2 and therefore medications that inhibit the enzyme will affect the clearance of tizanidine, leading to increased plasma concentrations of tizanidine and potentially serious adverse events."( A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS).
Boyce, RD; Gómez-Lumbreras, A; Horn, J; Malone, DC; Tan, MS; Villa-Zapata, L, 2022
)
0.72
"Our aim was to study the occurrence of adverse events reported in the FDA Adverse Event Reporting System (FAERS) involving the combination of tizanidine and drugs that inhibit the metabolic activity of CYP1A2."( A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS).
Boyce, RD; Gómez-Lumbreras, A; Horn, J; Malone, DC; Tan, MS; Villa-Zapata, L, 2022
)
0.72
"A disproportionality analysis of FAERS reports from 2004 quarter 1 through 2020 quarter 3 was conducted to calculate the reporting odds ratio (ROR) of reports mentioning tizanidine in a suspect or interacting role or having any role, a CYP1A2 inhibitor, and the following adverse events: hypotension, bradycardia, syncope, shock, cardiorespiratory arrest, and fall or fracture."( A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS).
Boyce, RD; Gómez-Lumbreras, A; Horn, J; Malone, DC; Tan, MS; Villa-Zapata, L, 2022
)
0.72
"A total of 89 reports were identified mentioning tizanidine, at least one CYP1A2 inhibitor, and one of the adverse events of interest."( A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS).
Boyce, RD; Gómez-Lumbreras, A; Horn, J; Malone, DC; Tan, MS; Villa-Zapata, L, 2022
)
0.72
"Outcomes were mortality, hospitalization, composite of hospitalization/emergency room visits, hypoxemia, requirement for supplemental oxygen, ventilator support, and serious adverse events."( Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Abbas, U; Deng, J; Garcia, C; Heybati, K; Huang, E; Moskalyk, M; Park, YJ; Ramaraju, HB; Rayner, D; Zhou, F, 2023
)
0.91
" Fluvoxamine was not associated with increased serious adverse events."( Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Abbas, U; Deng, J; Garcia, C; Heybati, K; Huang, E; Moskalyk, M; Park, YJ; Ramaraju, HB; Rayner, D; Zhou, F, 2023
)
1.82

Pharmacokinetics

Fluvoxamine shows a biphasic elimination with a mean terminal elimination half-life of about 15 to 20 hours. Fluvoxamine moderately increased the plasma concentrations and slightly prolonged the elimination half life of glimepiride. The objective of this study was to investigate pharmacokinetic and pharmacodynamic interactions between midazolam and fluoxetine.

ExcerptReferenceRelevance
"The pharmacokinetic properties of the newer specific serotonin (5-HT) reuptake inhibitors are reviewed."( Pharmacokinetics of the selective serotonin reuptake inhibitors.
DeVane, CL, 1992
)
0.28
"In a double-blind placebo-controlled study, the encephalotropic, psychotropic, pharmacodynamic and pharmacokinetic properties of 2 new substances, clovoxamine (a 5-HT and NE re-uptake inhibitor) and fluvoxamine (a selective 5-HT inhibitor) were investigated utilizing quantitative pharmaco-EEG, psychometric and blood level analyses."( Clovoxamine and fluvoxamine-2 biogenic amine re-uptake inhibiting antidepressants: quantitative EEG, psychometric and pharmacokinetic studies in man.
Grünberger, J; Karobath, M; Rajna, P; Saletu, B, 1980
)
0.8
" The terminal elimination half-life did not differ significantly between smokers and nonsmokers (10."( Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans.
Carleborg, L; Dahlqvist, R; Hedenmalm, K; Spigset, O, 1995
)
0.58
" From a clinical point of view, it is of relevance that potency to inhibit the cytochrome P450 isozyme CYP2D6 gradually decreases from paroxetine, fluoxetine, norfluoxetine, desmethylcitalopram, fluvoxamine, and sertraline down to citalopram, explaining to a great extent differences in pharmacokinetic interactions between the SSRIs and tricyclic antidepressants, which are metabolized by this enzyme."( Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Baumann, P; Rochat, B, 1995
)
0.48
" Following administration of single doses, fluvoxamine shows a biphasic elimination with a mean terminal elimination half-life of about 15 to 20 hours."( Clinical pharmacokinetics of fluvoxamine.
Gatti, G; Perucca, E; Spina, E, 1994
)
0.84
"We have assessed the pharmacokinetic and pharmacodynamic interaction between fluvoxamine, a serotonin reuptake inhibitor, and alprazolam, a triazolobenzo-diazepine."( A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.
Fleishaker, JC; Hulst, LK, 1994
)
0.73
" Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22."( Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects.
Avenoso, A; Campo, GM; Caputi, AP; Perucca, E; Pollicino, AM; Spina, E, 1993
)
0.94
" Mean (+/- SD) elimination half-life (t1/2) was 25 +/- 11h, and increased with higher plasma bilirubin levels, although no relationship between bilirubin and AUC was observed."( Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration.
de Vries, MH; Devissaguet, JP; Duchier, J; Raghoebar, M; van Bemmel, P; van Harten, J, 1993
)
0.61
" Plasma concentrations increased in a linear dose-dependent manner in the dose range between 25 and 100 mg; t1/2 and Tmax showed no significant differences among treatments."( Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects.
De Vries, MH; Raghoebar, M; Van Bemmel, P; Van Harten, J, 1993
)
0.61
" Fluvoxamine shows a biphasic pattern of elimination with a mean terminal elimination half-life of 12 to 15 hours after a single oral dose; this is prolonged by 30 to 50% at steady-state."( Overview of the pharmacokinetics of fluvoxamine.
van Harten, J, 1995
)
1.48
" According to a previous in vitro study, this pharmacokinetic interaction occurs on the level of CYP2C19, but also of CYP2D6 and CYP3A4 which, in contrast to CYP1A2, contribute to the N-demethylation of citalopram and which are stereoselectively inhibited by fluvoxamine."( Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation.
Baumann, P; Bertschy, G; Bondolfi, G; Chautems, C; Rochat, B, 1996
)
0.69
"The disposition characteristics and pharmacokinetic parameters of drugs provide fundamental data for designing safe and effective dosage regimens."( Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane, CL; Gill, HS, 1997
)
0.59
"The literature was searched for information related to the pharmacokinetic properties of fluvoxamine and reports of its involvement in drug interactions."( Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane, CL; Gill, HS, 1997
)
0.81
"The primary pharmacokinetic variables for fluvoxamine have been estimated in single and multiple dose studies in animals, health volunteers, and patients."( Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane, CL; Gill, HS, 1997
)
0.85
"Overall, the pharmacokinetic profile of fluvoxamine is adequately defined to provide guidelines for developing safe and effective dosage regimens for most types of patients."( Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane, CL; Gill, HS, 1997
)
0.86
" Pharmacokinetic interactions with other drugs have been described but, in some cases, their mechanism is unknown."( Pharmacokinetic interactions involving clozapine.
Taylor, D, 1997
)
0.3
"Published trials and case reports relevant to the human metabolism of clozapine and to suspected pharmacokinetic interactions were reviewed."( Pharmacokinetic interactions involving clozapine.
Taylor, D, 1997
)
0.3
" Pharmacokinetic parameters of fluvoxamine did not show any significant difference on the comparison between the groups."( The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy.
Miljković, BR; Pokrajac, M; Timotijević, I; Varagić, V, 1997
)
0.88
" Estimation of the mean elimination half-life of clozapine 2 weeks after start of fluvoxamine comedication revealed an increase from 17 hours to about 50 hours whereas there was no change under paroxetine coadministration."( Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study.
Anghelescu, I; Härter, S; Hiemke, C; Szegedi, A; Weigmann, H; Wetzel, H; Wiesner, J, 1998
)
0.74
" The half-life of buspirone was not affected."( The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone.
Kivistö, KT; Laitila, J; Lamberg, TS; Mårtensson, K; Neuvonen, PJ,
)
0.49
" However, this pharmacokinetic interaction was not associated with impairment of psychomotor performance and it is probably of limited clinical significance."( The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone.
Kivistö, KT; Laitila, J; Lamberg, TS; Mårtensson, K; Neuvonen, PJ,
)
0.49
" Serum concentrations of fluvoxamine, caffeine and paraxanthine were measured and standard pharmacokinetic parameters were calculated."( Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance.
Dahlqvist, R; Hägg, S; Söderström, E; Spigset, O, 1999
)
0.9
"We developed a two-compartment pharmacokinetic model to systematically characterize 19F magnetic resonance spectroscopy (19F MRS) data on the concentration time course of psychotropic compounds measured in human brain."( Characterization of human brain pharmacokinetics using a two-compartment model.
Dager, SR; Layton, ME; Strauss, WL, 1999
)
0.3
" They differ, however, in their pharmacokinetic properties."( Pharmacokinetics of selective serotonin reuptake inhibitors.
Härtter, S; Hiemke, C, 2000
)
0.31
" Fluvoxamine brain elimination half-life (79 +/- 24 hours; n = 4) was significantly shorter than that of CF-norfluoxetine (382 +/- 48 hours; n = 2)."( Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy.
Bolo, NR; Hodé, Y; Lainé, E; Macher, JP; Nédélec, JF; Wagner, G, 2000
)
1.46
" Our objective was to study the potential pharmacokinetic interaction between fluvoxamine and mexiletine."( Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men.
Fujimura, Y; Kusumoto, M; Mashimo, K; Nishihori, T; Oda, A; Takaya, K; Takeda, K; Tanaka, K; Ueno, K, 2001
)
0.94
"The area under the concentration-time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10."( Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men.
Fujimura, Y; Kusumoto, M; Mashimo, K; Nishihori, T; Oda, A; Takaya, K; Takeda, K; Tanaka, K; Ueno, K, 2001
)
0.71
" Fluvoxamine moderately increased the plasma concentrations and slightly prolonged the elimination half-life of glimepiride."( Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Backman, JT; Kivistö, KT; Laitila, J; Neuvonen, M; Neuvonen, PJ; Niemi, M, 2001
)
1.52
" FLV pharmacokinetic parameters (AUC, elimination half-life, Cmax and Tmax) did not significantly differ between the two groups."( Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.
Desai, HD; Flockhart, DA; Jan, MW; Kazmi, YR; VanDenBerg, CM; Weidler, DJ; ZumBrunnen, TL, 2002
)
0.64
" In this study, pharmacokinetic interactions and clinical effects of adding the CYP1A2 inhibitor fluvoxamine to steady-state olanzapine was examined in patients suffering from schizophrenia."( Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.
Hadjez, J; Härtter, S; Hiemke, C; Jabarin, M; Modai, I; Peled, A; Ritsner, M; Silver, H; Weigmann, H, 2002
)
1.97
"The objective of this study was to investigate pharmacokinetic and pharmacodynamic interactions between midazolam and fluoxetine, fluvoxamine, nefazodone, and ketoconazole."( Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.
Alfaro, CL; Ereshefsky, L; Lam, YW; Miller, M, 2003
)
0.74
" However, pharmacokinetic interactions between the two classes of drugs remain to be explored."( The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers.
Cai, ZJ; Li, WB; Wang, CY; Weng, YZ; Zhai, YM; Zhang, ZJ; Zhao, JP; Zhou, HH; Zhu, RH, 2004
)
0.59
"05) in heterozygous EMs, whereas no difference in any pharmacokinetic parameters was found in PMs."( Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Saito, M; Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N, 2004
)
0.71
" This study investigated the pharmacokinetic interactions between olanzapine and fluvoxamine in patients with schizophrenia."( Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia.
Chang, WH; Chiu, CC; Hon, YY; Huang, MC; Jann, MW; Lane, HY; Liu, HC; Lu, ML, 2004
)
0.77
"To determine the pharmacokinetics of fluvoxamine in children and adolescents and to compare pharmacokinetic data from adolescents to adults from a previous study."( Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents.
Biederman, J; Emslie, G; Ferguson, J; Khan, A; Labellarte, M; Riddle, M; Ruckle, J; Sallee, R, 2004
)
0.88
"Sixteen children (seven females, nine males) and 18 adolescents (nine females, nine males) were included in the pharmacokinetic analyses."( Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents.
Biederman, J; Emslie, G; Ferguson, J; Khan, A; Labellarte, M; Riddle, M; Ruckle, J; Sallee, R, 2004
)
0.6
"These pharmacokinetic results suggest that children (especially females) have a higher exposure to fluvoxamine than adolescents, whereas adolescents and adults appear to have similar exposure to fluvoxamine."( Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents.
Biederman, J; Emslie, G; Ferguson, J; Khan, A; Labellarte, M; Riddle, M; Ruckle, J; Sallee, R, 2004
)
0.82
"6), and prolonged its elimination half-life (4."( Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.
Culm-Merdek, KE; Greenblatt, DJ; Harmatz, JS; von Moltke, LL, 2005
)
1.77
"01) in heterozygous EMs, and significantly prolonged the elimination half-life of rabeprazole and rabeprazole thioether in homozygous EMs and in heterozygous EMs, whereas no difference in any pharmacokinetic parameters was found in PMs."( Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Shimizu, M; Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N, 2006
)
0.65
" During the fluvoxamine phase the area under the plasma concentration-time curve (AUC) and peak concentration (Cmax) of oral lidocaine were 305% (P<0."( Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.
Isohanni, MH; Neuvonen, PJ; Olkkola, KT, 2006
)
1.12
"The limitations of blood sampling in pharmacokinetic (PK)/pharmacodynamic (PD) studies in behavioral animal models could in part be overcome by a mixed effects modeling approach."( Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies.
Ahnaou, A; Danhof, M; Drinkenburg, WH; Freijer, J; Geldof, M; Timmerman, P; van Beijsterveldt, L, 2007
)
0.61
" This assay was demonstrated to be applicable for clinical pharmacokinetic studies."( HPLC method for the determination of fluvoxamine in human plasma and urine for application to pharmacokinetic studies.
Ulu, ST, 2007
)
0.61
"A pharmacokinetic (PK) model is proposed for estimation of total and free brain concentrations of fluvoxamine."( Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat.
Danhof, M; Freijer, J; Geldof, M; van Beijsterveldt, L, 2008
)
0.8
" Fluvoxamine pharmacokinetics was described by a population three-compartment pharmacokinetic model."( Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior.
Danhof, M; Freijer, J; Geldof, M; Megens, AA; van Beijsterveldt, L; Vermote, PC, 2007
)
1.49
" The most common adverse events and pharmacodynamic effects are related to plasma concentrations."( A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients.
Henney, HR; Runyan, JD, 2008
)
0.35
" The purpose of the present study was to clarify the pharmacokinetic interaction between tandospirone and fluvoxamine and to evaluate their combined effect in the rat anxiety model."( Pharmacokinetic interaction between tandospirone and fluvoxamine in the rat contextual conditioned fear stress model and its functional consequence: Involvement of cytochrome P450 3A4.
Inoue, T; Izumi, T; Koyama, T; Masui, T; Nakagawa, S; Nishikawa, H, 2008
)
0.81
" We investigated pharmacokinetic interactions following combined fluvoxamine and amitriptyline treatment and their impact on therapeutic efficacy and tolerability."( Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.
Miljkovic, B; Pokrajac, M; Prostran, M; Timotijevic, I; Todorovic, Z; Vezmar, S; Vucicevic, K, 2009
)
0.87
"With the exception of apparent distribution volume, ageing modified all main pharmacokinetic parameters of fluvoxamine."( Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure.
Andrighetto, L; De Martin, S; Floreani, M; Orlando, R; Palatini, P, 2010
)
2.02
"Using a three-compartment physiologically based pharmacokinetic (PBPK) model and a tube model for hepatic extraction kinetics, equations for calculating blood drug levels (Cb s) and hepatic blood drug levels (Chb s, proportional to actual hepatic drug levels), were derived mathematically."( Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions.
Iga, K, 2015
)
0.63
"The present review article describes the pharmacokinetic properties of fluvoxamine and their implications for the treatment of anxiety disorders (AD)."( Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders.
Altamura, AC; Buoli, M; Caldiroli, A, 2015
)
0.94
" Clopidogrel carboxylic acid was used for the pharmacokinetic study of clopidogrel."( Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats.
Bai, X; Chen, F; Fang, C; Han, M; Liu, M; Yang, G; Yang, Y; Zhao, J; Zhu, Q, 2015
)
0.82
" The aim of this work was to develop a physiologically based pharmacokinetic (PBPK)/pharmacodynamic (PD) model to predict changes in the PK parameters associated with genetic polymorphisms and the impact of these changes on drugs' PD effect."( Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs.
Alqahtani, S; Kaddoumi, A, 2016
)
0.43
"A physiologically based pharmacokinetic (PBPK) model was developed for cobimetinib using in vitro data."( Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha, NR; Chen, Y; Dresser, M; Eppler, S; Ji, T; Jin, JY; Musib, L, 2016
)
0.43
"The PBPK model described cobimetinib pharmacokinetic profiles after both intravenous and oral administration of cobimetinib well and accurately simulated the itraconazole-cobimetinib DDI."( Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha, NR; Chen, Y; Dresser, M; Eppler, S; Ji, T; Jin, JY; Musib, L, 2016
)
0.43
"Based on ibrutinib pharmacokinetics and potential sensitivity towards CYP3A4-mediated drug-drug interactions (DDIs), a physiologically based pharmacokinetic approach was developed to mechanistically describe DDI with various CYP3A4 perpetrators in healthy men under fasting conditions."( Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.
De Jong, J; de Zwart, L; Mannaert, E; Monshouwer, M; Snoeys, J; Sukbuntherng, J, 2016
)
0.43
" Therefore, the present study investigated a possible pharmacokinetic interaction between atomoxetine (ATX), a treatment option for ADHD, and an antidepressant, namely, fluvoxamine (FVX)."( Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers.
Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Todor, I; Vlase, L, 2017
)
0.88
" Non-compartmental methods were employed to determine the pharmacokinetic parameters of ATX and its main active metabolite (glucuronidated form), 4-hydroxyatomoxetine-O-glucuronide."( Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers.
Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Todor, I; Vlase, L, 2017
)
0.68
" The presence or absence of any clinical consequences associated with this pharmacokinetic drug-drug interaction needs to be established in future studies."( Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers.
Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Todor, I; Vlase, L, 2017
)
0.68
"To investigate whether fluvoxamine coadministration can influence the pharmacokinetic properties of nebivolol and its active hydroxylated metabolite (4-OH-nebivolol) and to assess the consequences of this potential pharmacokinetic interaction upon nebivolol pharmacodynamics."( Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers.
Achim, M; Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Todor, I; Tomuta, I; Vlase, L, 2017
)
0.99
" Non-compartmental analysis was used to determine the pharmacokinetic parameters of nebivolol and its active metabolite."( Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers.
Achim, M; Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Todor, I; Tomuta, I; Vlase, L, 2017
)
0.68
" Pharmacokinetic analyses of the CYP2C19 probe drug, omeprazole, were performed before and after rifampicin or fluvoxamine administration."( Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype.
Hakamata, A; Inui, N; Kamiya, C; Miyakawa, S; Namiki, N; Odagiri, K; Tanaka, S; Uchida, S; Watanabe, H, 2019
)
0.73
" To identify antidepressants less likely to cause hyponatremia, we conducted a triangulation study integrating retrospective cohort, disproportionality, and pharmacodynamic studies."( Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies.
Akimoto, H; Asai, S; Hayakawa, T; Minagawa, K; Nagashima, T; Takahashi, Y, 2022
)
0.72

Compound-Compound Interactions

Fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain. 30 of 37 inpatients with severe OCD were followed up 6-8 years after treatment with cognitive-behavioral therapy.

ExcerptReferenceRelevance
" Psychological panic management combined with exposure was not superior to exposure alone of equal duration."( Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone.
de Beurs, E; Koele, P; Lange, A; van Balkom, AJ; van Dyck, R, 1995
)
0.53
"The effects of fluvoxamine (50 or 100 mg), alone and in combination with ethanol (0."( Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers.
Eckardt, MJ; George, DT; Lane, E; Linnoila, M; Stapleton, JM, 1993
)
1.03
"The overall reporting rate of drug-drug interactions with fluvoxamine is very low: only 73 cases have been identified from an estimated exposure of over 8 million patients worldwide."( Fluvoxamine. A review of global drug-drug interaction data.
Vause, EW; Wagner, W, 1995
)
1.98
" To minimize the potential for an adverse event, the practitioner must remember the drug-drug interactions, and possible consequences when one of these antidepressants is being prescribed."( Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs.
Richelson, E, 1997
)
0.3
"The purpose of this treatment package design study was to investigate the differential efficacy of cognitive therapy or exposure in vivo with response prevention for obsessive compulsive disorder (OCD) versus the sequential combination with fluvoxamine."( Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder.
de Haan, E; Hoogduin, KA; Spinhoven, P; van Balkom, AJ; van Dyck, R; van Oppen, P, 1998
)
0.72
"The aim of the present study was to evaluate the use of recombinant human cytochrome P-450 1A2 (rH-CYP1A2) in studies performed in vitro in order to predict metabolic drug-drug interactions occurring in man."( Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man.
Beaune, P; Becquemont, L; Funck-Brentano, C; Jaillon, P; Le Bot, MA; Riche, C, 1998
)
0.53
"The drug-drug interaction between fluvoxamine (FLV) and clozapine (CLZ) was evaluated by in-vitro and in-vivo methods."( In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine.
Augustin, B; Chang, WH; Jann, MW; Kazmi, Y; Lane, HY; Liu, HC; ZumBrunnen, T, 1999
)
0.82
"1 mg/kg) in combination with fluvoxamine also caused a selective increase in extracellular DA levels in the cortex."( Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex.
Ago, Y; Baba, A; Matsuda, T; Nakamura, S, 2005
)
0.91
" In the current study, 30 of 37 inpatients (81%) with severe OCD were followed up 6-8 years after treatment with cognitive-behavioral therapy (CBT) in combination with either fluvoxamine or placebo in a randomized design."( Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.
Alsleben, H; Braatz, A; Fricke, S; Hand, I; Katenkamp, B; Ortmann, J; Peter, H; Rufer, M, 2005
)
0.73
" Our study is the first to examine the long-term effectiveness of cognitive therapy (CT) and to compare long-term effectiveness of CT alone, exposure in vivo with response prevention (ERP) alone, and CBT (either CT or ERP) in combination with fluvoxamine in the treatment of OCD."( Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up.
de Haan, E; van Balkom, AJ; van Dyck, R; van Oppen, P, 2005
)
0.74
" These results further support the previous suggestion that the cortical dopamine system plays an important role in the effects of antipsychotic drugs administered in combination with fluvoxamine."( Lack of enhanced effect of antipsychotics combined with fluvoxamine on acetylcholine release in rat prefrontal cortex.
Ago, Y; Baba, A; Matsuda, T; Nakamura, S; Sato, M, 2006
)
0.77
" Variables included in the analysis were age, gender, and concomitant treatment with a total of 41 drugs most often used in combination with quetiapine."( Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service.
Castberg, I; Skogvoll, E; Spigset, O, 2007
)
0.34
" On the basis of our data and pharmacokinetic considerations, the majority of drugs commonly used in psychiatry can safely be given in combination with quetiapine."( Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service.
Castberg, I; Skogvoll, E; Spigset, O, 2007
)
0.34
"The aim of this crossover human male volunteer study was to investigate the utility of microdosing in the investigation of drug-drug interactions."( Predicting drug candidate victims of drug-drug interactions, using microdosing.
Croft, M; Keely, B; Lappin, G; Morris, I; Tann, L, 2012
)
0.38
" The changes in pharmacokinetics mediated by ketoconazole and fluvoxamine were quantitatively consistent with previously reported, non-microdose, drug-drug interaction data from studies including the same compounds."( Predicting drug candidate victims of drug-drug interactions, using microdosing.
Croft, M; Keely, B; Lappin, G; Morris, I; Tann, L, 2012
)
0.62
"The initial data reported here demonstrate the utility of microdosing to investigate the risk of development drugs being victims of drug-drug interactions."( Predicting drug candidate victims of drug-drug interactions, using microdosing.
Croft, M; Keely, B; Lappin, G; Morris, I; Tann, L, 2012
)
0.38
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" Drugs were selected based not only on the knowledge that the 6-hydroxylation of exogenous melatonin, its principal pathway of metabolism, is mainly mediated by hepatic CYP1A2, but also on the likelihood of the drug being concurrently administered with melatonin."( Potential drug interactions with melatonin.
Ioannides, C; Papagiannidou, E; Skene, DJ, 2014
)
0.4
" Little is known about pomalidomide's potential for drug-drug interactions (DDIs); as pomalidomide clearance includes hydrolysis and cytochrome P450 (CYP450)-mediated hydroxylation, possible DDIs via CYP450 and drug-transporter proteins were investigated in vitro and in a clinical study."( Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.
Assaf, M; Hoffmann, M; Kasserra, C; Kumar, G; Li, Y; Liu, L; Palmisano, M; Wang, X, 2015
)
0.42
"To observe treatment effects and safety of fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain."( Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain.
Ca, LH; Chang, J; Huang, XE; Huang, XH; Liu, J; Ma, YM; Wei, W; Wu, YJ; Xiao, Y; Zhang, RX, 2014
)
1
"Fluvoxamine combined with oxycodone prolonged-release tablets could be more effective in treating patients with cancer pain, and could reduce the dosage of oxycodone prolonged-release tablets and thus be associated with lower side effects, and improved quality of life."( Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain.
Ca, LH; Chang, J; Huang, XE; Huang, XH; Liu, J; Ma, YM; Wei, W; Wu, YJ; Xiao, Y; Zhang, RX, 2014
)
2.18
" Assuming the actual values for total body clearance (CLtot ), oral bioavailability (F), and steady-state distribution volume (Vdss ), Cb s, and Chb s after intravenous and oral administration of fluvoxamine (strong perpetrator in drug-drug interactions, DDIs), propranolol, imipramine, and tacrine were simulated."( Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions.
Iga, K, 2015
)
0.82
"Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance prediction."( Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.
Azuma, J; Kato, M; Kinoshita, T; Nonen, S; Serretti, A; Takekita, Y; Wakeno, M, 2015
)
0.42
" Tasimelteon is rapidly absorbed, with a mean absolute bioavailability of approximately 38%, and is extensively metabolized primarily by oxidation at multiple sites, mainly by cytochrome P450 (CYP) 1A2 and CYP3A4/5, as initially demonstrated by in vitro studies and confirmed by the results of clinical drug-drug interactions presented here."( Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist.
Baroldi, P; Dressman, MA; Kramer, WG; Ogilvie, BW; Torres, R, 2015
)
0.42
"Fluvoxamine-perpetrated drug-drug interactions (DDIs) of victims metabolized by multiple cytochrome P450 isoforms (CYP1A2, CYP2C19, and CYP3A4) were simulated using 2 compartment-based tube modeling, assuming a multiple inhibition-constant (Ki) model, as well as a previously reported single Ki model."( Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Vic
Iga, K, 2016
)
2.16
" A clinical drug-drug interaction (DDI) study with the potent CYP3A4 inhibitor itraconazole resulted in an approximately sevenfold increase in cobimetinib exposure."( Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha, NR; Chen, Y; Dresser, M; Eppler, S; Ji, T; Jin, JY; Musib, L, 2016
)
0.43
"Our study of drug-drug interaction (DDI) started with the clarification of unusually large DDI observed between ramelteon (RAM) and fluvoxamine (FLV)."( Usefulness of Two-Compartment Model-Assisted and Static Overall Inhibitory-Activity Method for Prediction of Drug-Drug Interaction.
Iga, K; Kiriyama, A, 2017
)
0.66
"
 Conclusion: Fluvoxamine combined with MPH-ER is effective in the treatment of refractory obsessive-compulsive disorder."( [Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder].
Guo, G; Huang, H; Jia, F; Li, G; Quan, D; Zheng, H, 2018
)
1.21
" Molecular array data resulted in identifying the specific and key players participating in cancer progression when the drug combination was used."( Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy.
Kumar, N; Raza, M; Sehrawat, S, 2021
)
0.62

Bioavailability

This study showed an increase in the bioavailability of oral melatonin by coadministration of fluvoxamine. Fluvoxamine is well absorbed after oral administration, widely distributed in the body, and eliminated with a mean half-life of 15 hours.

ExcerptReferenceRelevance
" They are well absorbed orally but exhibit an extensive first-pass extraction in the liver."( Pharmacokinetics of the selective serotonin reuptake inhibitors.
DeVane, CL, 1992
)
0.28
" Paroxetine is well absorbed from the gastrointestinal tract and undergoes first-pass metabolism that is partially saturable."( The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
Johnson, AM; Tulloch, IF, 1992
)
0.28
" Despite complete absorption, oral bioavailability may be incomplete probably because of first-pass metabolism."( Clinical pharmacokinetics of fluvoxamine.
Gatti, G; Perucca, E; Spina, E, 1994
)
0.58
" Despite complete absorption, oral bioavailability in man is approximately 50% on account of first-pass hepatic metabolism."( Overview of the pharmacokinetics of fluvoxamine.
van Harten, J, 1995
)
0.57
" Fluvoxamine is well absorbed after oral administration, widely distributed in the body, and eliminated with a mean half-life of 15 hours and a range from 9 hours to 28 hours."( Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane, CL; Gill, HS, 1997
)
1.5
"This study showed an increase in the bioavailability of oral melatonin by coadministration of fluvoxamine."( Increased bioavailability of oral melatonin after fluvoxamine coadministration.
Grözinger, M; Härtter, S; Hiemke, C; Röschke, J; Weigmann, H, 2000
)
0.78
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Observations of brain fluoxetine bioavailability and elimination half-life also were similar between age groups."( Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
Cowan, C; Dager, SR; Dawson, G; Strauss, WL; Unis, AS, 2002
)
0.56
" The bioavailability of omeprazole might, to some extent, be increased through inhibition of P-glycoprotein during fluvoxamine treatment."( Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
Inoue, Y; Kaneko, S; Nakagami, T; Takahata, T; Tateishi, T; Yasui-Furukori, N; Yoshiya, G, 2004
)
0.82
" In the presence of fluvoxamine, the oral bioavailability of duloxetine increased from 42."( In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.
Bergstrom, RF; Chappell, J; Hong, Q; Knadler, MP; Lobo, ED; Quinlan, T; Reddy, S; Ring, B, 2008
)
0.67
"Targeting serotonin (5-HT) bioavailability with selective 5-HT reuptake inhibitors (SSRIs) remains the most widely used treatment for mood disorders."( Regulator of G-protein signaling 6 (RGS6) promotes anxiety and depression by attenuating serotonin-mediated activation of the 5-HT(1A) receptor-adenylyl cyclase axis.
Fisher, RA; Maity, B; Meng, F; Stewart, A; Wemmie, JA; Wu, Q; Wunsch, AM, 2014
)
0.4
" Assuming the actual values for total body clearance (CLtot ), oral bioavailability (F), and steady-state distribution volume (Vdss ), Cb s, and Chb s after intravenous and oral administration of fluvoxamine (strong perpetrator in drug-drug interactions, DDIs), propranolol, imipramine, and tacrine were simulated."( Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions.
Iga, K, 2015
)
0.82
" Tasimelteon is rapidly absorbed, with a mean absolute bioavailability of approximately 38%, and is extensively metabolized primarily by oxidation at multiple sites, mainly by cytochrome P450 (CYP) 1A2 and CYP3A4/5, as initially demonstrated by in vitro studies and confirmed by the results of clinical drug-drug interactions presented here."( Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist.
Baroldi, P; Dressman, MA; Kramer, WG; Ogilvie, BW; Torres, R, 2015
)
0.42
"Two phase 1 studies characterized the oral bioavailability of AZD4635 (potential anticancer therapy) and factors that may influence its pharmacokinetics (PKs; food, smoking, proton-pump inhibitors [PPIs] and CYP1A2 inhibitors) to support continued clinical development of AZD4635."( Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerations.
Alcobi, R; Forte, P; Graham, L; Jung, L; Li, Y; Moorthy, G; Mugundu, G; Pilling, E; Pouliot, GP; Sidhu, S; Zhu, Y, 2023
)
0.91
"The results showed that CYP2C19 inhibitors could significantly improve the bioavailability of mavacamten in rats, which indicated that we should pay more attention to the patient's condition to prevent the occurrence of side effects when used mavacamten in combination with CYP2C19 inhibitors."( Effects of CYP2C19 inhibitors on mavacamten pharmacokinetics in rats based on UPLC-MS/MS.
Chen, C; Li, Q; Liu, YN; Xie, S; Xu, RA; Zhan, R, 2023
)
0.91

Dosage Studied

The aim of this study was to investigate whether obsessive-compulsive patients could tolerate reduction of the daily dosage without worsening of the clinical condition. Patients received fluvoxamine, a novel anti-depressant, over a treatment period of 6 weeks, dosage starting at either 50 or 100 mg at night.

ExcerptRelevanceReference
"The pharmacology and pharmacokinetics, adverse effects, drug interactions, efficacy, and dosage and administration of the new selective serotonin reuptake inhibitors paroxetine, sertraline, and fluvoxamine are reviewed."( Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.
Grimsley, SR; Jann, MW, 1992
)
0.77
" Also the terminal half-life after chronic dosing (22 +/- 6 h) tended to be longer than after single dosing."( Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects.
de Vries, MH; Mathlener, IS; Raghoebar, M; van Harten, J, 1992
)
0.57
"In 3 patients the addition of fluvoxamine to a constant dosage of carbamazepine (CZP) caused a substantial rise of plasma CZP accompanied by symptoms of intoxication."( Interaction between carbamazepine and fluvoxamine.
Fritze, J; Lanczik, M; Unsorg, B, 1991
)
0.84
" These can be divided into those associated with: pharmacokinetics, polypharmacy, side effects, dosage and lethality."( The elderly depressed and treatment with fluvoxamine.
Phanjoo, A, 1991
)
0.55
" The dosage of both drugs was 50 mg nocte for three days, 100 mg nocte for the remainder of the first week, thereafter increasing to a maximum of 200 mg/day according to response/tolerance."( A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients.
Akhtar, MJ; Ashford, JJ; Kellett, JM; Rahman, MK; Savla, NC; Sharma, RR, 1991
)
0.55
" Patients were allocated at random to receive one or other drug for a period of 4 weeks, dosage starting at 50 mg for the first 3 days and increasing to 100 mg daily for a further 3 days."( Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study.
Baignoli, G; Ecari, U; Gonella, G, 1990
)
1.72
" Active treatment was for 6 weeks with an initial dose of either 100 mg fluvoxamine or 60 mg mianserin; after 1 week the dosage could be increased to 300 mg or 180 mg, respectively."( A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness.
Ashford, JJ; Perez, A, 1990
)
0.78
" Patients received fluvoxamine, a novel anti-depressant, over a treatment period of 6 weeks, dosage starting at either 50 or 100 mg at night increasing after the first week, if necessary, to a maximum of 300 mg per day."( Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine.
Ashford, JJ; Martin, AJ; Tebbs, VM, 1987
)
0.83
" Therapy was initiated at 50 mg/day; thereafter, dosage ranged between 100 and 300 mg/day for both drugs."( A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.
Dominguez, RA; Goldstein, BJ; Jacobson, AF; Steinbook, RM, 1985
)
0.53
" All three dosage regimens produced significant improvement and no significant difference was found in antidepressive effect between the groups."( The tolerance and antidepressive activity of fluvoxamine as a single dose compared to a twice daily dose.
Chakravarti, SK; Jesinger, DK; Siddiqui, UA, 1985
)
0.53
" Its effective dosage is 100 mg to 200 mg/day."( A Belgian multicentre study of fluvoxamine in depressive outpatients.
Ansseau, M; Bartholome, F; Brasseur, R; Mesotten, F; Uytdenhoef, P; Van Moffaert, M,
)
0.42
" Thirty-two patients with mixed depression received one or the other drug at the same daily dosage of 150 mg."( A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine.
Dick, P; Ferrero, E, 1983
)
0.51
" In the first study the effects of a single daily dosage of between 100 and 300 mg of fluvoxamine were compared with those of chlorimipramine at a dosage of 50-150 mg daily in 43 out-patients with endogenous depression."( Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing.
De Wilde, JE; Mertens, C; Wakelin, JS, 1983
)
0.82
" The major side effects in therapeutic dosage include heart rate increase, postural hypotension and slight prolongation of the intraventricular conduction time and QT interval."( Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine.
Roos, JC, 1983
)
0.49
" Fluvoxamine has a rapid action with lifting of the mood often within 4-7 days, in a dosage range from 150 to 200 mg/day."( Long-term study of fluvoxamine: a new rapid-acting antidepressant.
Denber, HC; Feldmann, HS, 1982
)
1.5
" dosage was maintained between 150 and 300 mg per day."( Fluvoxamine maleate, a serotonergic antidepressant; a comparison with chlorimipramine.
Block, BA; Coleman, BS, 1982
)
1.71
" The overall antidepressant efficacy of fluvoxamine 100 to 300 mg/day for 4 to 6 weeks in once daily or divided dosage regimens appears to be at least comparable to that of imipramine and similar to that of clomipramine, dothiepin, desipramine, amitriptyline, lofepramine, maprotiline, mianserin and moclobemide."( Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.
Benfield, P; Plosker, GL; Wilde, MI, 1993
)
2
"The serotonin uptake inhibitor fluvoxamine was assessed in treatment of alcohol-induced Korsakoff's syndrome (KS) using fixed (4 weeks, 200 mg/day) or individualized (6 weeks, plasma concentration > or = 400 ng/ml) dosing in randomized placebo-controlled double-blind crossover studies."( Fluvoxamine treatment of alcoholic amnestic disorder.
Adinoff, B; Bone, GA; Eckardt, MJ; Lane, E; Linnoila, M; Martin, PR; Stapleton, JM; Weingartner, H, 1995
)
2.02
" They were administered the drug at a daily dosage of 100 mg in the evening."( Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects.
Gambini, O; Grassi, B; Scarone, S, 1995
)
0.61
" Dosage of fluvoxamine, duration of treatment, interval between last dosage and blood collection were associated with effects on plasma concentrations that were consistent with the pharmacokinetic profile of fluvoxamine."( Determination of fluvoxamine concentration in plasma by reversed-phase liquid chromatography.
DellaFera, S; Fernandes, R; Kranzler, HR; Wong, SH,
)
0.86
" Despite a lower daily fluvoxamine dosage in the mild group, the premature terminator rate in this group (47%) was higher than in the moderate group (27%) or in the severe group (24%)."( The efficacy of fluvoxamine in patients with severe depression.
Ottevanger, EA, 1994
)
0.95
" A recent panel study suggests that determination of CYP1A2 activity with the caffeine test may be very useful for the dosing of clozapine."( Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service.
Bertilsson, L; Bondesson, U; Jerling, M; Lindström, L, 1994
)
1.73
" The dosage of alprazolam should be reduced during co-administration with fluvoxamine."( A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.
Fleishaker, JC; Hulst, LK, 1994
)
0.74
" Addition of fluvoxamine to patients on a stable desipramine dosage regimen resulted in a slight, but statistically not significant, increase in desipramine plasma concentrations."( Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients.
Avenoso, A; Campo, GM; Caputi, AP; Pollicino, AM; Spina, E, 1993
)
2.1
"Manic symptomatology resolved in all eight patients following dosage reduction or withdrawal of fluvoxamine."( Fluvoxamine-associated manic behavior: a case series.
Aronzon, R; Bar-Halperin, A; Dorevitch, A; Frankel, Y; Zilberman, L, 1993
)
1.95
" These findings indicate that, at the dosage tested, fluvoxamine markedly inhibits the demethylation of imipramine without affecting significantly the CYP2D6-mediated hydroxylation of desipramine."( Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects.
Avenoso, A; Campo, GM; Caputi, AP; Perucca, E; Pollicino, AM; Spina, E, 1993
)
0.94
"The antinociceptive effect of three antidepressants with different postulated modes of action, 75 mg desipramine, 225 mg fluvoxamine, and 450 mg moclobemide, was evaluated after single oral dosing in a randomized, double-blind, placebo-controlled crossover study in 10 healthy volunteers."( Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers.
Coquoz, D; Dayer, P; Porchet, HC, 1993
)
0.76
" Although there was a fixed-flexible dosage design it was apparent that 16 patients (89%) of the fluvoxamine group and all patients of the maprotiline group received a dosage between 200 and 300 mg/day in the last week of the trial."( Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects.
Dötsch, M; Kasper, S; Kick, H; Möller, HJ; Vieira, A, 1993
)
0.81
" Indeed, planned pharmacokinetic drug interactions at the level of P450s have been proposed to reduce cyclosporine dosage requirements, to reduce variability of TCA levels, and to manipulate the contribution of alternative metabolic pathways to minimize toxic effects."( Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II.
Harvey, AT; Preskorn, SH, 1996
)
0.29
"The aim of this study was to investigate whether obsessive-compulsive patients previously treated successfully with clomipramine or fluvoxamine could tolerate reduction of the daily dosage without worsening of the clinical condition."( Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study.
Bareggi, SR; Bellodi, L; Mundo, E; Pirola, R; Smeraldi, E, 1997
)
0.5
" The dose-response curve was biphasic for citalopram with a maximum of 64% inhibition."( Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Meier, E; Sánchez, C, 1997
)
0.3
" The dosage was titrated upward weekly to a maximum dosage of 150 mg/d."( Fluvoxamine for stereotypic behavior in patients with dementia.
Trappler, B; Vinuela, LM, 1997
)
1.74
"With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy."( Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD, 1997
)
0.3
"Sixty patients were randomly assigned to receive dosage titrated upward to between 50-150 mg/day of fluvoxamine (N = 30) or 20-50 mg/day of paroxetine (N = 30)."( A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.
Feiger, A; Kiev, A, 1997
)
0.8
"The disposition characteristics and pharmacokinetic parameters of drugs provide fundamental data for designing safe and effective dosage regimens."( Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane, CL; Gill, HS, 1997
)
0.59
" Data from elderly subjects reflect a modest need for dosage adjustment in this population."( Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane, CL; Gill, HS, 1997
)
0.59
"Overall, the pharmacokinetic profile of fluvoxamine is adequately defined to provide guidelines for developing safe and effective dosage regimens for most types of patients."( Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane, CL; Gill, HS, 1997
)
0.86
" Eight healthy subjects were given fluvoxamine in increasing dosage from 25 mg/day to 200 mg/day during 4 weeks, and serum sodium and serum prolactin concentrations were obtained weekly."( The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status.
Mjorndal, T; Spigset, O, 1997
)
0.93
" In order to investigate whether treatment with a selective serotonin reuptake inhibitor affects platelet 5-HT2A receptors, we have studied platelet [3H]lysergic acid diethylamide ([3H]LSD) binding in healthy subjects treated with fluvoxamine in increasing dosage once weekly for 4 weeks."( Effect of fluvoxamine on platelet 5-HT2A receptors as studied by [3H]lysergic acid diethylamide ([3H]LSD) binding in healthy volunteers.
Mjörndal, T; Spigset, O, 1997
)
0.88
" Thus, in all patients, fluvoxamine induced relevant increases in serum concentrations of clozapine and its metabolites, probably by the inhibition of enzymes catalyzing the degradation of clozapine and N-desmethylclozapine, whereas paroxetine, at a usual clinically effective dosage of 20 mg/day, did not cause significant pharmacokinetic interactions."( Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study.
Anghelescu, I; Härter, S; Hiemke, C; Szegedi, A; Weigmann, H; Wetzel, H; Wiesner, J, 1998
)
0.82
" Average daily dosage of fluvoxamine was 160 mg, with a highest permitted dose of 300 mg/day."( Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine.
Bandelow, B; Benkert, O; Härtter, S; Hiemke, C; Lörch, B; Sandmann, J; Winter, P, 1998
)
2.05
" In patients with partial response, the dosage should be increased to the maximum by 5-9 weeks."( Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature.
Ellingrod, VL,
)
0.13
"In a randomised, double-blind design, 30 patients were treated for nine weeks with BT plus placebo and 30 patients with BT plus fluvoxamine (maximum dosage 300 mg, mean dose 288."( Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study.
Aldenhoff, J; Berger, M; Geiger-Kabisch, C; Hand, I; Hiss, H; Hohagen, F; Käppler, C; König, A; Münchau, N; Rasche-Rüchle, H; Rey, E; Schramm, P; Winkelmann, G, 1998
)
0.78
"This pilot study examined prospectively blood serum concentrations of fluvoxamine, side effects and therapeutic response after a fixed dosage of 100 mg fluvoxamine/day for 14 days."( Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial.
Hammes, E; Härtter, S; Hiemke, C; Torkzadeh, M; Wetzel, H, 1998
)
0.84
" 50 mg FLUVOX were given throughout the study period, while the CLOZ dosage was increased individually (week 5: 96."( Coadministration of clozapine and fluvoxamine in psychotic patients--clinical experience.
Deuschle, M; Härtter, S; Heese, C; Heuser, I; Hiemke, C; Lammers, CH; Weigmann, H, 1999
)
0.58
" Ten patients (5 men and 5 women) completed an active 6 week treatment period of flexible dosing (50-150 mg/day)."( Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia.
Brawman-Mintzer, O; DeVane, CL; Emmanuel, NP; Lydiard, RB; Morton, WA; Villarreal, G; Ware, MR, 1999
)
0.54
" Concentrations of THD, mesoridazine, and sulforidazine were measured in plasma samples obtained from 10 male inpatients, aged 36 to 78 years, at three different time points: A, during habitual monotherapy with THD at 88 +/-54 mg/day; B, after addition of a low dosage of fluvoxamine (25 mg twice a day) for 1 week; and C, 2 weeks after fluvoxamine discontinuation."( Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
Agundez, JA; Benítez, J; Berecz, R; Carrillo, JA; Duran, M; Herraiz, AG; Llerena, A; Ramos, SI, 1999
)
0.77
"In patients unable to maintain an effective methadone blood level throughout the dosing interval, fluvoxamine can help increase the methadone blood level and alleviate opiate withdrawal symptoms."( A therapeutic use of the methadone fluvoxamine drug interaction.
DeMaria, PA; Serota, RD, 1999
)
0.8
" We coadministered a low dosage of levomepromazine and fluvoxamine in 15 patients and found that the low dosage of levomepromazine was effective in counteracting the fluvoxamine-induced insomnia and did not increase plasma fluvoxamine levels."( Low dosage of levomepromazine did not increase plasma concentrations of fluvoxamine.
Nakamura, J; Ueda, N; Yoshimura, R, 2000
)
0.79
"Fifty-seven highly recurrent unipolar patients, excluded from previous long-term studies with selective serotonin reuptake inhibitors (SSRIs) after they experienced a new recurrence, were acutely treated with the full dosage of the SSRIs they were on."( Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes?
Bongiorno, F; Franchini, L; Rossini, D; Smeraldi, E; Spagnolo, C; Zanardi, R, 2000
)
0.31
"Concomitant fluvoxamine use can potentially reduce the dosage of clozapine needed in treatment-refractory patients with schizophrenia."( Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.
Chang, WH; Chen, KP; Jann, MW; Lane, HY; Lu, ML; Su, MH, 2000
)
2.13
" Only slight dosage adjustments with clozapine may be needed after fluvoxamine coadministration in some patients who smoke."( Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.
Chang, WH; Chen, KP; Jann, MW; Lane, HY; Lu, ML; Su, MH, 2000
)
1.99
" Dose-response studies showed that the potency of cyanopindolol to inhibit clearance of 5-HT was equivalent to that of the selective 5-HT reuptake inhibitor fluvoxamine."( 5-HT(1B) receptor-mediated regulation of serotonin clearance in rat hippocampus in vivo.
Daws, LC; Frazer, A; Gerhardt, GA; Gould, GG; Teicher, SD, 2000
)
0.5
" No further seizures occurred after he was placed on a higher dosage of the anticonvulsants."( Seizure possibly associated with fluvoxamine.
Craig, JM; Hawley, JM; Kim, KY, 2000
)
0.59
"The patient presented here developed a seizure with a therapeutic dosage of fluvoxamine; seizures associated with this agent have occurred more often with overdose."( Seizure possibly associated with fluvoxamine.
Craig, JM; Hawley, JM; Kim, KY, 2000
)
0.82
"1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed."( Phenytoin intoxication induced by fluvoxamine.
Higuchi, S; Ieiri, I; Kojima, K; Mamiya, K; Ninomiya, H; Tashiro, N; Yukawa, E, 2001
)
0.93
" Absorption of fluvoxamine was similar in adolescents to that in adults, which suggests that the maximum dosage of the drug for patients aged between 12 and 17 years can be as high as 300 mg/day."( Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents.
Cheer, SM; Figgitt, DP, 2001
)
2.11
" Absorption of fluvoxamine was similar in adolescents to that in adults, which suggests that the maximum dosage of the drug for patients aged between 12 and 17 years can be as high as 300 mg/day."( Spotlight on fluvoxamine in anxiety disorders in children and adolescents.
Cheer, SM; Figgitt, DP, 2002
)
1.04
" One EM subject had a very low oral clearance of fluvoxamine after both single and multiple dosing of the drug."( Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Andersson, K; Bertilsson, L; Carrillo, JA; Christensen, M; Dahl, ML; Mihara, K; Ramos, SI; Tybring, G; Yasui-Furokori, N, 2002
)
0.85
" In addition, the different dose-response to fluvoxamine suggests that 5-HT(1B) knockout mice have possible adaptations of 5-HT transporters in order to compensate for the loss of the terminal 5-HT(1B) autoreceptor."( The effects of selective serotonin reuptake inhibitors on extracellular 5-HT levels in the hippocampus of 5-HT(1B) receptor knockout mice.
De Groote, L; Olivier, B; Westenberg, HG, 2002
)
0.57
" Little is known about the age-related brain pharmacokinetics of SSRIs; there is a lack of data regarding optimal dosing of medications for children."( Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
Cowan, C; Dager, SR; Dawson, G; Strauss, WL; Unis, AS, 2002
)
0.56
"For paroxetine and fluoxetine, plasma concentrations and dosage strongly influence the magnitude of enzyme inhibition."( CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
Alfaro, CL; Ereshefsky, L; Gaedigk, A; Lam, YW; Simpson, J, 2002
)
0.31
"FLV disposition and dosing is unlikely to be affected by CYP2C19 polymorphism."( Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.
Desai, HD; Flockhart, DA; Jan, MW; Kazmi, YR; VanDenBerg, CM; Weidler, DJ; ZumBrunnen, TL, 2002
)
0.64
" Fluvoxamine was prescribed up to 200 mg/day in the dosing protocol for 6 weeks."( A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine.
Higuchi, H; Inoue, K; Ito, K; Itoh, K; Kamata, M; Ohkubo, T; Otani, K; Sato, K; Shimizu, T; Sugawara, K; Suzuki, T; Takahashi, H; Tezuka, T; Yoshida, K, 2002
)
1.43
" Fluvoxamine has an extensive elimination half-life of 17-22 hours after a single dose, which increases with multiple dosing by 30-50%."( Fluvoxamine interaction with warfarin.
Elliott, ES; Limke, KK; Shelton, AR, 2002
)
2.67
" The authors investigated whether a functional polymorphism in the MAOA gene promoter (MAOA-VNTR) and a TPH gene polymorphism in intron 7 (TPH-A218C) were associated with the antidepressant response to fluvoxamine in 66 Japanese patients with major depressive disorder during a 6-week study with a specific dosage plan."( Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder.
Higuchi, H; Inoue, K; Ito, K; Itoh, K; Kamata, M; Naito, S; Ohkubo, T; Otani, K; Sato, K; Shimizu, T; Sugawara, K; Suzuki, T; Takahashi, H; Tezuka, T; Yoshida, K, 2002
)
0.71
" The methods of fluvoxamine treatment, such as appropriate dosage and treatment duration, should also be clarified."( [Serotonin 2A receptor gene polymorphism and clinical efficacy of fluvoxamine in children with autistic disorder].
Fukuda, T; Ito, M; Ohzeki, T; Sugie, H; Sugie, Y, 2003
)
0.9
" Therefore, a careful dosing strategy starting with a low dose might be effective for avoiding emesis associated with the clinical use of fluvoxamine."( Possible involvement of peripheral serotonin 5-HT3 receptors in fluvoxamine-induced emesis in Suncus murinus.
Baba, J; Fujiwara-Sawada, M; Imanishi, T; Yoshida, A, 2003
)
0.76
" The dose-response was compared and the initial significant clinical action was examined."( Suitable dose and duration of fluvoxamine administration to treat depression.
Arita, S; Morishita, S, 2003
)
0.61
"To investigate the relationship between 5-HTT occupancy and a wide range of antidepressant dosing protocols."( High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography.
Ichimiya, T; Ikoma, Y; Inoue, M; Okubo, Y; Sudo, Y; Suhara, T; Takano, A; Yasuno, F, 2003
)
0.53
" This method has been used for the simultaneous determination of steady-state plasma concentration (Css) of fluvoxamine and fluvoxamino acid in depressive patients treated with 200 mg of oral fluvoxamine dosed as 100 mg twice-daily."( High-performance liquid chromatographic determination of fluvoxamine and fluvoxamino acid in human plasma.
Higuchi, H; Ohkubo, T; Otani, K; Shimizu, T; Shimoyama, R; Yoshida, K, 2003
)
0.78
" Fluvoxamine was administered for 6 weeks with a specific dosage plan (50-200 mg/day) in 66 Japanese major depressive patients."( Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine.
Higuchi, H; Inoue, K; Ito, K; Itoh, K; Kamata, M; Naito, S; Ohkubo, T; Sato, K; Shimizu, T; Suzuki, T; Takahashi, H; Yoshida, K, 2003
)
1.44
" Using the methods, the type of CYP2C19 gene was examined in 80 inpatients, and the medication status of patients with the mutation was examined focusing on dosage and side effects."( [Analysis and its application for prevention of side-effects of drugs and for evaluation of drug responsiveness].
Inoue, K, 2004
)
0.32
" The dosage remained constant during weeks 6 to 12."( Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder.
Barbato, LM; Davidson, J; DuPont, R; Li, D; Stallings, L; van der Hoop, RG; Yaryura-Tobias, J, 2004
)
1.77
" If this combined treatment is applied, conservative introduction with reduced clozapine dosage and careful therapeutic drug monitoring of clozapine concentration is recommended."( Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.
Chang, WH; Chen, KP; Lane, HY; Lin, SK; Lu, ML, 2004
)
0.71
" Multiple SSRI dosing ranges were evaluated in autistic patients of different ages with various functional impairments."( Treating functional impairment of autism with selective serotonin-reuptake inhibitors.
Eichner, SF; Jones, JR; Moore, ML, 2004
)
0.32
" The failure to improve without an adequate dosage of LT4 suggests that hypothyroidism was probably an aggravating factor."( Coexistent hypothyroidism, psychosis, and severe obsessions in an adolescent: a 10-year follow-up.
Alshari, MG; Bhatara, A; Bhatara, V; McMillin, JM; Warhol, P, 2004
)
0.32
"The influence of dosing time on the anti-immobility effect of antidepressants and mechanisms underlying this phenomenon were investigated in mice."( Chronopharmacological study of antidepressants in forced swimming test of mice.
Higuchi, S; Koyanagi, S; Ohdo, S; Sakaguchi, H; Sato, Y; To, H; Ushijima, K, 2005
)
0.33
"The absence of significant differences in efficacy between selective serotonin re-uptake inhibitors (SSRIs) and imipramine in these trials is at least in part due to improper dosing of the latter; imipramine with therapeutic drug monitoring may be more effective than SSRIs."( Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?
Birkenhäger, TK; Bruijn, JA; Moleman, P; van den Broek, WW; Vulto, AG, 2005
)
0.33
" In a randomized, double-blind, placebo-controlled, crossover study, we evaluated the effects of fluvoxamine dosed to steady state on the pharmacokinetics and pharmacodynamics of sildenafil."( Fluvoxamine affects sildenafil kinetics and dynamics.
Burhenne, J; Haefeli, WE; Hesse, C; Riedel, KD; Siedler, H, 2005
)
1.99
" 101 patients maintained the same full dosage treatment after remission from a depressive episode efficaciously treated with fluvoxamine."( Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychosocial and genetic variables.
Bongiorno, F; Dotoli, D; Franchini, L; Serretti, A; Smeraldi, E; Spagnolo, C; Zanardi, R, 2006
)
0.79
" A lower and flexible reboxetine dosing schedule will be recommended for future research to improve its tolerability in PTSD patients."( Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial.
Kotler, M; Shabash, E; Shaked, G; Spivak, B; Strous, RD; Weizman, A, 2006
)
0.67
"After a drug-free period and four days of placebo use, patients were randomised either to imipramine or to fluvoxamine (phase 1); the antidepressant dosage was fixed according to a predetermined plasma level."( [Comparison of the effectiveness of two treatment strategies in inpatients with a depressive disorder. A double-blind study of imipramine followed by lithium addition versus fluvoxamine followed by lithium addition].
Birkenhäger, TK; Bruijn, JA; Moleman, P; Mulder, PG; van den Broek, WW, 2006
)
0.74
" This symptom gradually abated within a week and when the dosage of milnacipran was increased to 100 mg day(-1) at 2 months, no further piloerection occurred."( Piloerection induced by replacing fluvoxamine with milnacipran.
Hazui, T; Hori, S; Matsuo, N; Miki, A; Nakano, M; Ohtani, H; Sawada, Y; Suzuki, Y; Yagi, H; Yamamoto, A, 2007
)
0.62
" She was started on fluvoxamine, and the dosage was gradually increased."( Effects of fluvoxamine on behavioral and psychological symptoms of dementia in Alzheimer's disease: a report of three cases.
Kurita, M; Mashiko, H; Nakahata, N; Nishino, S; Niwa, S; Ohtomo, K; Sato, T; Shirakawa, H, 2006
)
1.05
"5 and 24 h after the last dosage of chronic treatment (30 days), with haloperidol plus fluvoxamine, each drug alone, and clozapine."( Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment.
Chertkow, Y; Silver, H; Weinreb, O; Youdim, MB, 2007
)
0.79
"To investigate the effects of steady-state dosing of fluvoxamine, an inhibitor of cytochrome P450 (CYP) 1A2 and CYP2C19, on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor and its pharmacodynamically active metabolite roflumilast N-oxide."( Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
Hermann, R; Herzog, R; Huennemeyer, A; Lahu, G; von Richter, O; Zech, K, 2007
)
0.99
"0), their satisfaction reasons were elicited by three multiple-choice responses: efficacy, fewer side effects, and lower dosing frequency."( Patient satisfaction with antidepressants: an Internet-based study.
Nomura, S; Sato, Y; Shigemura, J; Yoshino, A, 2008
)
0.35
" Milnacipran above the dosage of 10 mg/kg inhibited marble burying behavior significantly in mice as similar to fluvoxamine."( Effects of the serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran on marble burying behavior in mice.
Hotta, Y; Kobayashi, Y; Sugimoto, Y; Tagawa, N; Yamada, J, 2007
)
0.55
"5 yr of age) were randomly assigned to receive a dosage of 50 mg/day of fluvoxamine (n=53) or 20 mg/day of paroxetine (n=52)."( Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.
Ikeda, A; Ueki, M; Ushiroyama, T, 2004
)
0.82
"Tizanidine, one of the few oral antispastic therapies approved for use in the USA, has a narrow therapeutic index that can often make optimal patient dosing difficult."( A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients.
Henney, HR; Runyan, JD, 2008
)
0.35
" Practical advice on tizanidine dosing and/or switching between formulations is provided."( A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients.
Henney, HR; Runyan, JD, 2008
)
0.35
" Dosing of fluvoxamine started with an initial morning dose of 50 mg on Day 3, followed by a twice daily (12-h interval) dosing of 50 mg on Days 4-12."( The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects.
den Adel, M; Kadokura, T; Krauwinkel, WJ; Nishida, A; Takeshige, T, 2008
)
1.1
"Selective serotonin reuptake inhibitors were found to be effective in treating premenstrual symptoms, with continuous dosing regimens favored for effectiveness."( Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis.
Aperi, J; Borenstein, J; Jones, JB; Karne, A; Shah, NR; Shemtov, R, 2008
)
0.35
" Amitriptyline had the highest effect in dosage 50 mg daily but was not well tolerated by patients that resulted in that only 50% of them finished the study."( [Fluvoxamine, amitriptyline and transcranial electrostimulation of the brain in the treatment of chronic daily headache].
Amelin, AV; Skoromets, AA; Tarasova, SV, 2008
)
1.26
", differences in the type and degree of liver dysfunction of the animals and patients examined, and in the type and dosage of the inducing agent used."( Enzyme inhibition and induction in liver disease.
De Martin, S; Orlando, R; Palatini, P; Pegoraro, P, 2008
)
0.35
" In vivo assessment of CYP1A2 and CYP3A4 activities, perhaps by phenotyping approaches, could assist the optimization of CLZ dosage and minimize pharmacokinetic interactions with coadministered drugs."( Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
D'Esposito, F; Edwards, RJ; Murray, M; Ramzan, I; Zhang, WV, 2008
)
0.35
"A highly sensitive and simple spectrofluorimetric method has been developed and validated for the determination of the antidepressant fluvoxamine (FXM) in its dosage forms and plasma."( Spectrofluorimetric determination of fluvoxamine in dosage forms and plasma via derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole.
Abdine, HH; Al-Rayes, LI; Amer, SM; Darwish, IA, 2009
)
0.83
" We report on the case of a 42-year-old depressive female patient with comorbid migraine attacks, whereby the adjunction of topiramate as an antimigraine agent at the dosage of 50 mg/d to her antidepressive treatment with fluvoxamine at 300 mg/d triggered--the prima facie paradoxical for topiramate--side effects of tremor and myoclonus."( Reversible tremor and myoclonus associated with topiramate-fluvoxamine coadministration.
Kouzoupis, AV; Masdrakis, VG; Oulis, P; Potagas, C; Soldatos, CR; Thomopoulos, Y,
)
0.56
" This color-developing reaction was successfully employed in the development of simple and rapid spectrophotometric method for determination of FXM in its pharmaceutical dosage forms."( Spectrophotometric study for the reaction between fluvoxamine and 1,2-naphthoquinone-4-sulphonate: Kinetic, mechanism and use for determination of fluvoxamine in its dosage forms.
Abdine, HH; Al-Rayes, LI; Amer, SM; Darwish, IA, 2009
)
0.61
" Pharmacokinetic data from drug-development studies in rats often determine the dosage used in human clinical trials."( Three-dimensional quantitative structure-activity relationship analysis of inhibitors of human and rat cytochrome P4503A enzymes.
Gouda, H; Handa, K; Hirono, S; Nakagome, I; Yamaotsu, N, 2013
)
0.39
" Patients of the control group received antidepressants only (fevarin in dosage 150 mg daily)."( [The effect of mexidol in the combination with antidepressants on sleep disturbance in young patients with panic disorder].
Kursakov, ES; Remizevich, RS, 2013
)
0.39
" We conducted an 8-week, rater-blinded, randomized trial, administering flexibly dosed risperidone, yokukansan, or fluvoxamine."( Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial.
Kurita, M; Nishino, S; Numata, Y; Okubo, Y; Sato, T; Takeyoshi, K; Tateno, A; Teranishi, M, 2013
)
0.84
"Fluvoxamine combined with oxycodone prolonged-release tablets could be more effective in treating patients with cancer pain, and could reduce the dosage of oxycodone prolonged-release tablets and thus be associated with lower side effects, and improved quality of life."( Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain.
Ca, LH; Chang, J; Huang, XE; Huang, XH; Liu, J; Ma, YM; Wei, W; Wu, YJ; Xiao, Y; Zhang, RX, 2014
)
2.18
" We calculated the ratio of the mean doses for each study and weighted it by the total sample size to find the weighted mean ratio for each drug, which was then used to define the drug׳s dosage equivalent to fluoxetine 40mg/d."( Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015
)
0.42
" In the primary analysis, fluoxetine 40mg/day was equivalent to paroxetine dosage of 34."( Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015
)
0.42
" Using this method, the ramelteon-victimized DDI could be simulated in comparison with other victim DDIs, assuming a consistent FLV dosing regimen."( Simulation of Metabolic Drug-Drug Interactions Perpetrated by Fluvoxamine Using Hybridized Two-Compartment Hepatic Drug-Pool-Based Tube Modeling and Estimation of In Vivo Inhibition Constants.
Iga, K, 2015
)
0.66
" The present study was designed to clarify the relationship between dosage and treatment response in major depressive disorder."( Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL, 2016
)
0.43
" Endpoint and tolerability analyses were analyzed using meta-regression and stratified subgroup analysis by predefined SSRI dose categories in order to assess the effect of SSRI dosing on the efficacy and tolerability of SSRIs for major depressive disorder."( Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL, 2016
)
0.43
" The DDI risk for cobimetinib with other CYP3A4 inhibitors and inducers needs to be assessed in order to provide dosing instructions."( Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha, NR; Chen, Y; Dresser, M; Eppler, S; Ji, T; Jin, JY; Musib, L, 2016
)
0.43
"This study demonstrates the value of using PBPK simulation to assess the clinical DDI risk inorder to provide dosing instructions with other CYP3A4 perpetrators."( Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha, NR; Chen, Y; Dresser, M; Eppler, S; Ji, T; Jin, JY; Musib, L, 2016
)
0.43
"Pomalidomide is an immunomodulatory drug, and the dosage of 4 mg per day taken orally on days 1-21 of repeated 28-day cycles has been approved in the European Union and the United States to treat patients with relapsed/refractory multiple myeloma."( In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
Hoffmann, M; Li, Y; Liu, L; Palmisano, M; Reyes, J; Wang, X; Zhang, C; Zhou, S, 2018
)
0.48
"The proposed method was applied successfully for the analysis of the cited drugs in pure and dosage forms."( Non-extractive spectrophotometric determination of memantine HCl, clomipramine HCl and fluvoxamine maleate in pure form and in pharmaceutical products by ion-pair complex formation with rose bengal.
El-Alfy, W; El-Mammli, MY; Ismaiel, OA; Sayed, RA; Shalaby, A, 2021
)
0.84
" More data are needed on dosing and mechanisms of effect; however, fluvoxamine appears to have substantial potential as a safe and widely available medication that could be repurposed to ameliorate serious COVID-19-related morbidity and mortality."( Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
Boulware, DR; Facente, SN; Klausner, JD; Lenze, EJ; Reiersen, AM, 2021
)
2.3
"It is important to consider the effects of DDIs on the abrocitinib active moiety when making dosing recommendations."( Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.
Connell, CA; Dowty, ME; Le, VH; Malhotra, BK; O'Gorman, MT; Tatulych, S; Tripathy, S; Valdez, H; Wang, X; Winton, JA; Wouters, A; Yin, N, 2022
)
0.72
" However, optimal dosage regimens and the trade-off with drug-drug interactions remain unclear."( Pharmacogenetic Aspects of COVID-19 Management and Post-COVID-19 Depression Treatment with Fluvoxamine.
Abdyrahmanova, A; Astafeva, D; Cumming, P; Davydkin, I; De Sousa, A; Dobrodeeva, V; Nasyrova, R; Shnayder, N; Smirnova, D; Yashikhina, A, 2022
)
0.94
" Genotype-guided dosing and drug selection have been implemented at several sites, including Vanderbilt University Medical Center, where clinical decision support (CDS) based on pharmacogenetic results went live for selective serotonin reuptake inhibitors in 2020 for both adult and pediatric patients."( Pediatric considerations for pharmacogenetic selective serotonin reuptake inhibitors clinical decision support.
Liu, M; Maxwell-Horn, AC; Rossow, KM; Saucier, LA; Van Driest, SL, 2023
)
0.91
" Different dosing regimens may have contributed to the contradictory findings."( Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Abbas, U; Deng, J; Garcia, C; Heybati, K; Huang, E; Moskalyk, M; Park, YJ; Ramaraju, HB; Rayner, D; Zhou, F, 2023
)
0.91
"To evaluate the efficacy and safety of SSRIs and the effect of different dosing regimens on the treatment of acute COVID-19."( Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Abbas, U; Deng, J; Garcia, C; Heybati, K; Huang, E; Moskalyk, M; Park, YJ; Ramaraju, HB; Rayner, D; Zhou, F, 2023
)
0.91
" The medication must be continued for at least 12 weeks at an effective dosage to find the most effective SSRI."( Remission of treatment-resistant obsessive-compulsive disorder with 600 milligrams of fluvoxamine daily: a case report.
Altindağ, A; Demir, B; Kocamer Şahin, Ş, 2023
)
1.13
" Mianserin and mirtazapine (separately) induced dose-dependent antinociception, each one yielding a biphasic dose-response curve, and they were antagonized by naloxone."( Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
Keidan, L; Pick, CG; Schreiber, S, 2023
)
0.91
"In this study, a new green microwell spectrofluorimetric assay (MW-SFA) with high throughput was developed and validated, for the first time, for the determination of three selective serotonin reuptake inhibitors (SSRIs) in pharmaceutical dosage forms and plasma."( Development of a Green Microwell Spectrofluorimetric Assay with High Analytical Throughput for the Determination of Selective Serotonin Reuptake Inhibitors in Pharmaceutical Dosage Forms and Plasma.
Alzoman, NZ; Darwish, IA, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
serotonin uptake inhibitorA compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.
anxiolytic drugAnxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
5-methoxyvalerophenone O-(2-aminoethyl)oxime
(trifluoromethyl)benzenesAn organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (81)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NFKB1 protein, partialHomo sapiens (human)Potency5.62340.02827.055915.8489AID895; AID928
TDP1 proteinHomo sapiens (human)Potency18.52550.000811.382244.6684AID686978; AID686979
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency11.89610.00137.762544.6684AID914; AID915
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency12.17430.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.38770.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency16.06440.00636.904339.8107AID883
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.81270.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.04470.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency12.92440.316212.765731.6228AID881
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency15.09830.00638.235039.8107AID881; AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.81271.000012.224831.6228AID885
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency16.08670.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency9.26650.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency18.50610.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743042; AID743054
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency29.84930.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency11.88320.001022.650876.6163AID1224838
progesterone receptorHomo sapiens (human)Potency21.13170.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency7.76190.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency18.99590.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency25.75650.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency14.24490.000817.505159.3239AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency2.98490.001530.607315,848.9004AID1224841; AID1224842; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency13.33320.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.46540.000229.305416,493.5996AID1259244; AID743079
GVesicular stomatitis virusPotency10.96400.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency0.97720.00108.379861.1304AID1645840
arylsulfatase AHomo sapiens (human)Potency0.01071.069113.955137.9330AID720538
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency21.13170.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency29.84930.001628.015177.1139AID1259385
activating transcription factor 6Homo sapiens (human)Potency9.52050.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency23.914519.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency13.97420.057821.109761.2679AID1159528
D(1A) dopamine receptorHomo sapiens (human)Potency14.12540.02245.944922.3872AID488981
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency12.58930.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency13.71430.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency13.33220.000627.21521,122.0200AID743202
survival motor neuron protein isoform dHomo sapiens (human)Potency7.94330.125912.234435.4813AID1458
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency9.43920.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency22.12900.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency9.43920.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency35.48130.009610.525035.4813AID1479145
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency10.00001.000010.475628.1838AID1457
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
Ataxin-2Homo sapiens (human)Potency22.38720.011912.222168.7989AID588378
cytochrome P450 2C9, partialHomo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2 Rattus norvegicus (Norway rat)Ki57.40000.00030.30010.8700AID624686
Tryptophan 5-hydroxylase 1Rattus norvegicus (Norway rat)Ki0.00150.00050.09140.4900AID64525
Cytochrome P450 2D6Homo sapiens (human)Ki12.50000.00011.19868.0000AID1220287; AID1220288
Cytochrome P450 2C9 Homo sapiens (human)Ki8.50000.00031.684210.0000AID54410
DRattus norvegicus (Norway rat)IC50 (µMol)0.54000.00030.50267.7625AID179927
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.54000.00030.39075.4000AID179927
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.54000.00030.35635.4000AID179927
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.54000.00030.38715.4000AID179927
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)0.00380.00010.86458.7096AID1718178
Sodium-dependent serotonin transporterHomo sapiens (human)Ki0.23050.00000.70488.1930AID1783169; AID64522
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)IC50 (µMol)0.54000.00030.81978.4900AID179927
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.54000.00010.54948.4000AID179927
Sodium-dependent dopamine transporter Homo sapiens (human)Ki0.00150.00021.11158.0280AID64525
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)3.10000.00091.901410.0000AID1207216
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)39.40000.00033.64849.2000AID1207157
Sigma intracellular receptor 2Rattus norvegicus (Norway rat)Ki8.43900.00241.10509.3000AID1718151
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.03600.00000.490110.0000AID712773
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Ki0.03600.00030.26715.0700AID1718165; AID675979
TransporterRattus norvegicus (Norway rat)IC50 (µMol)0.54000.00081.95628.8000AID179927
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (202)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (90)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (66)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (163)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346955Rat SERT (Monoamine transporter subfamily)2001Neurochemistry international, Jul, Volume: 39, Issue:1
Pharmacological characterization and visualization of the glial serotonin transporter.
AID1346943Human SERT (Monoamine transporter subfamily)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1210013Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation assessed as remaining activity at 30 uM after 5 mins by LC-MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1215121Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID675979Displacement of [3H]-(+)pentazocine from rat brain sigma 1-type opioid receptor2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Thiophene bioisosteres of spirocyclic σ receptor ligands: relationships between substitution pattern and σ receptor affinity.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1220555Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1207157Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID681144TP_TRANSPORTER: cell accumulation of calcein in L-MDR1 cells2003The Journal of pharmacology and experimental therapeutics, Apr, Volume: 305, Issue:1
Inhibition of P-glycoprotein by newer antidepressants.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID54410Binding affinity towards cytochrome P450 2C92004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.
AID204863Inhibition constant in rat serotonin transporter;ND means no data.2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1718178Inhibition of SERT (unknown origin)2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID229148Ratio of inhibition of 5-HT to inhibition of dopamine (5-HT/DA); ND means no data.2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1718151Displacement of [3H]DTG from sigma 2 receptor in Sprague-Dawley rat brain membranes in presence of (+)-pentazocine by scintillation counting method2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID712772Binding affinity to sigma 2 receptor2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.
AID29813Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID624686Mechanism based inhibition of rat cytochrome P450 CYP1A2 measured by zolmitriptan metabolism2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1210014Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation assessed as remaining activity at 30 uM after 5 mins by LC-MS/MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1308025Inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate at 10 uM preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis relative to control2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker.
AID1220556Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID679765TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Fluvoxamine: 100 uM) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID1220288Inhibition of CYP2D6 (unknown origin) assessed as desipramine oxidation2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681116TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID298032Acid dissociation constant, pKa of the compound2007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1207651Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1718165Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in Sprague-Dawley rat brain membranes by scintillation counting method2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID712773Binding affinity to sigma 1 receptor2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID143648Inhibition constant in rat NE transporter;ND means no data.2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1207216Inhibition of hERG K channel2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1220558Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID204209Inhibition constant against [N-methyl-3H]WIN-35428 in murine kidney cells transfected with human dopamine transporter;ND means no data2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.
AID479103Antistress activity against isolation-induced aggressive behavior in ICR mouse assessed as duration of attacks to intruder mouse at 30 mg/kg, po measured for 10 mins by resident-intruder test (RVb = 54.5 +/- 6.7 sec)2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1220559Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1220287Inhibition of CYP2D6 (unknown origin) assessed as sparteine oxidation2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID179927Inhibition of 5-HT uptake in synaptosomal preparation from rat corpus striatum, using [3H]5-HT1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1207247Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID229149Ratio of inhibition of 5-HT to inhibition of dopamine (5-HT/DA) in murine kidney cells transfected with human serotonin transporter;ND means no data2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID179960Inhibition of dopamine uptake in synaptosomal preparation in rat corpus striatum, using [3H]dopamine1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins.
AID64522Inhibition constant against [3H]citalopram in murine kidney cells transfected with human dopamine transporter2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.
AID1220554Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1215122Percentage unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID1220557Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID64525In vitro competitive binding versus [N-methyl-3H]WIN-35428 in murine kidney cells transfected with cDNA for human dopamine transporter (DAT)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678718Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID298031Lipophilicity, log D at pH7.42007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID1220560Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1783169Displacement of [3H]citalopram from human SERT in HEK293 cells by Topcount scintillation analysis2021European journal of medicinal chemistry, Aug-05, Volume: 220Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands - Fluoxetine and fluvoxamine.
AID65511Inhibition constant in rat dopamine transporter;ND means no data.2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID479102Antistress activity against isolation-induced aggressive behavior in ICR mouse assessed as duration of attacks to intruder mouse at 7.5 mg/kg, po measured for 10 mins by resident-intruder test (RVb = 54.5 +/- 6.7 sec)2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.
AID1207186Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1215126Ratio of fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID179973Inhibition of norepinephrine uptake in synaptosomal preparation fro rat hypothalamus, using [3H]norepinephrine1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,937)

TimeframeStudies, This Drug (%)All Drugs %
pre-199097 (5.01)18.7374
1990's627 (32.37)18.2507
2000's717 (37.02)29.6817
2010's345 (17.81)24.3611
2020's151 (7.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 99.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index99.73 (24.57)
Research Supply Index7.85 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index183.77 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (99.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials518 (25.26%)5.53%
Reviews0 (0.00%)6.00%
Reviews224 (10.92%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies336 (16.38%)4.05%
Observational0 (0.00%)0.25%
Observational1 (0.05%)0.25%
Other6 (100.00%)84.16%
Other972 (47.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (69)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (FluCOP Trial) [NCT05216614]Phase 20 participants (Actual)Interventional2021-12-14Withdrawn(stopped due to Unable to obtain investigational product)
Fluvoxamine for Early Treatment of Covid-19: a Fully-remote, Randomized Placebo Controlled Trial [NCT04668950]Phase 3670 participants (Actual)Interventional2020-12-22Completed
Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel. a Randomized, Double-blind Placebo Controlled, Crossover Trial [NCT01269333]Phase 115 participants (Actual)Interventional2011-01-31Completed
A PHASE 1, OPEN-LABEL, RANDOMIZED, FIXED-SEQUENCE, PARALLEL-COHORT STUDY TO ESTIMATE THE EFFECT OF FLUVOXAMINE OR FLUCONAZOLE, ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A SINGLE DOSE OF PF-04965842 IN HEALTHY SUBJECTS [NCT03634345]Phase 124 participants (Actual)Interventional2018-09-12Completed
An Open-Label, One-Sequence, Two-Part Drug-Drug Interaction Study in Healthy Volunteers to Assess the CYP1A2 and CYP3A4 Perpetrator Interaction Potential and CYP1A2 Victim Potential of TEV-56286 (anle138b) [NCT05532358]Phase 154 participants (Actual)Interventional2022-09-12Completed
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications [NCT05894564]Phase 31,188 participants (Actual)Interventional2022-08-25Completed
Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics [NCT03219008]Phase 4800 participants (Anticipated)Interventional2017-08-01Recruiting
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants [NCT03511118]1,600 participants (Anticipated)Observational2018-10-04Recruiting
A Phase I, Open-label, Fixed-sequence Study to Assess the Effects of Strong CYP1A2 Inhibitor (Fluvoxamine) on Savolitinib Exposure in Healthy Male Subjects [NCT05888207]Phase 116 participants (Actual)Interventional2023-06-02Completed
An Adaptive, Randomized, doublE-blind, Placebo-controlled, Prospective, Pharmacological interVention Study In Participants With Long COVID-19 Syndrome: REVIVE-TOGETHER Trial [NCT06128967]Phase 31,500 participants (Anticipated)Interventional2023-10-18Recruiting
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury [NCT02320240]3,255,526 participants (Actual)Observational2013-06-30Completed
A Two Part, Fixed-sequence, Open-label Crossover Study to Evaluate Potential CYP1A2-mediated Drug-drug Interactions of ABX464 in Healthy Subjects Using Caffeine and Fluvoxamine as Probe Drugs [NCT05121714]Phase 159 participants (Actual)Interventional2020-12-17Completed
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications [NCT05890586]Phase 31,331 participants (Actual)Interventional2021-06-08Completed
An Open-label, Single-sequence Study to Investigate the Effects of Cytochrome P450 1A2 Inhibition on the Pharmacokinetics of BMS-986165 in Healthy Participants [NCT03930602]Phase 116 participants (Actual)Interventional2019-05-01Completed
A Multicenter, Prospective, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Interferon Lambda 1A, Fluvoxamina + Budesonida, Fluoxetina + Budesonida in Mild COVID-19 and High Risk of Complications [NCT04727424]Phase 36,246 participants (Anticipated)Interventional2021-01-19Recruiting
[NCT02194075]Phase 460 participants (Actual)Interventional2013-10-31Completed
A Clinical Trial of Fluvoxamine for Melancholia [NCT04160377]Phase 2150 participants (Anticipated)Interventional2019-08-01Recruiting
A Phase 1, Open-Label, Fixed-Sequence Crossover Study to Evaluate the Effect of a Strong Inhibitor of Cytochrome P450 2C19 on the Pharmacokinetics of Miricorilant in Healthy Subjects [NCT05712265]Phase 126 participants (Actual)Interventional2023-01-24Completed
Cost-Effectiveness of Adding Web-Based CBT to Luvox CR for OCD [NCT00743834]Phase 450 participants (Anticipated)Interventional2008-09-30Not yet recruiting
The Use of Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Major Depressive Disorder [NCT00157547]Phase 495 participants (Actual)Interventional2003-04-30Completed
Phase I Study of FK949E - A Study of Drug-drug Interactions Between FK949E and Fluvoxamine in Healthy Male Adults [NCT01908296]Phase 124 participants (Actual)Interventional2011-07-31Completed
Open Label, Non-comparative Study to Evaluate Cognitive Functioning in Remitted Depression Outpatients During Long-term Preventive Treatment With Fluvoxamine [NCT02016261]Phase 450 participants (Actual)Interventional2013-12-31Completed
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies [NCT02893371]1,037,352 participants (Actual)Observational2016-09-30Completed
Shanghai Mental Health Center in China [NCT02739061]142 participants (Actual)Interventional2014-06-12Completed
Alterations in mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) of Schizophrenia Patients Treated With Fluvoxamine Augmentation of Antipsychotics: Relationship to Clinical Symptoms and Cognitive Function [NCT00645580]15 participants (Anticipated)Interventional2008-04-30Active, not recruiting
A Double-Blind Placebo-Controlled Randomized Clinical Trial of Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood? [NCT00655174]Phase 3108 participants (Actual)Interventional1999-06-30Completed
Influence of Fluvoxamine on the Pharmacokinetics of BI 409306 After Oral Administration (Randomized, Open-label, Two-treatment, Two-sequence, Two-period Crossover Study) [NCT02853136]Phase 118 participants (Actual)Interventional2016-08-25Completed
Impact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel, a Randomized, Double-blind, Crossover Trial [NCT01396720]Phase 115 participants (Actual)Interventional2011-09-30Completed
Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine [NCT01401491]Phase 480 participants (Actual)Interventional2008-01-31Completed
A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection [NCT04342663]Phase 2152 participants (Actual)Interventional2020-04-10Completed
A Phase I, Randomized, Two-Period, Single-Center Study to Assess the Effect of CYP2D6 and CYP2C19 Inhibitors on a Single Oral Dose of AV650 (300 mg) in Healthy Subjects [NCT00456560]Phase 130 participants (Anticipated)Interventional2007-04-30Completed
Impact of Genetic Polymorphism on Drug Interactions Involving CYP2C19: Risk of Phenoconversion in Healthy CYP2C19 Fast, Normal and Intermediate Metabolizers Status [NCT05264142]Phase 145 participants (Anticipated)Interventional2022-04-01Recruiting
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications [NCT04885530]Phase 315,000 participants (Anticipated)Interventional2021-06-08Active, not recruiting
SME3110 (Fluvoxamine Maleate) in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placebo-controlled Study [NCT00352768]Phase 420 participants (Actual)Interventional2006-08-31Terminated(stopped due to This study was prematurely terminated (26 June 2009) due to slow recruitment)
Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder [NCT02022709]Phase 478 participants (Actual)Interventional2014-01-31Completed
An Open-label, Single-sequence Study in Healthy Subjects to Evaluate the Single-dose Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP1A2 Inhibitor, Fluvoxamine [NCT01540500]Phase 124 participants (Actual)Interventional2012-02-29Completed
A Treatment Study of Youth With Comorbid Attention Deficit Hyperactivity Disorder (ADHD) and Anxiety Disorders [NCT00012584]120 participants Interventional2000-11-30Completed
Fluvoxamine for Adults With Mild to Moderate COVID-19: A Single-blind, Randomized, Placebo-controlled Trial [NCT04711863]Phase 2400 participants (Anticipated)Interventional2021-01-16Suspended(stopped due to Closure of main community treatment center)
Treatment of Pediatric OCD for SRI Partial Responders [NCT00074815]Phase 3124 participants (Actual)Interventional2003-09-30Completed
Pharmacokinetic and Pharmacodynamic Evaluation of the Interaction Between Fluvoxamine and Sildenafil in Healthy Males [NCT00175981]Phase 112 participants Interventional2003-02-28Completed
[NCT02655354]635 participants (Actual)Interventional2015-10-31Completed
A Single-Center, Open-Label, One-Sequence, Crossover Study to Investigate the Effects of Multiple Doses of Fluvoxamine on the Pharmacokinetics of a Single Dose RO4917523 in Healthy Subjects [NCT01665404]Phase 116 participants (Actual)Interventional2012-07-31Completed
A Phase I, Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effect of the CYP1A2 Inhibitor, Fluvoxamine, on Dovitinib (TKI258) Pharmacokinetics in Patients With Advanced Solid Tumors [NCT01700270]Phase 145 participants (Actual)Interventional2013-05-31Completed
[NCT01704638]Phase 114 participants (Actual)Interventional2008-08-31Completed
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects [NCT01707407]Phase 132 participants (Actual)Interventional2012-09-01Completed
Algorithm Guided Treatment Strategies for Major Depressive Disorder [NCT01764867]Phase 41,080 participants (Anticipated)Interventional2012-06-30Recruiting
Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child [NCT01796132]Phase 4500 participants (Anticipated)Interventional2012-08-31Recruiting
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) [NCT04510194]Phase 31,323 participants (Actual)Interventional2021-01-01Active, not recruiting
The Study of Mindfulness Based Cognitive Therapy and Obsessive-Compulsive Disorder [NCT03179839]123 participants (Actual)Interventional2017-01-20Completed
Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder [NCT01460212]Phase 480 participants (Anticipated)Interventional2011-12-31Recruiting
A Pilot Study Examining the Gut Microbiota in Patients With Obsessive-Compulsive Disorder vs. Healthy Controls and Following 12-weeks of Open-label Selective Serotonin Reuptake Inhibitors Treatment [NCT02285699]43 participants (Anticipated)Interventional2014-11-01Completed
A Randomized, Double-blind, Placebo-controlled, Adaptive-design Study to Assess the Safety and Efficacy of Daily 200 mg Fluvoxamine as add-on Therapy to Standard of Care in Moderate Severity COVID-19 Patients [NCT04718480]Phase 266 participants (Actual)Interventional2020-11-27Completed
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression [NCT01896349]74 participants (Anticipated)Interventional2013-04-30Recruiting
Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community With Fluvoxamine, Bromhexine, Cyproheptadine, and Niclosamide in Decreasing Recovery Time [NCT05087381]Phase 41,200 participants (Actual)Interventional2021-10-01Completed
Assessing Tolerability and Efficacy of Vortioxetine Versus SSRIs in Elderly Patients With Depression: a Pragmatic, Multicenter, Open-label, Parallel-group, Superiority, Randomized Trial [NCT03779789]Phase 4362 participants (Actual)Interventional2019-02-01Completed
Effect of Fluvoxamine Augmentation on Cognitive Function , Aggressive Behavior , Clinical Symptoms and mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) in Medicated Schizophrenia Patients [NCT01832285]40 participants (Anticipated)Interventional2012-12-31Recruiting
SME3110 (Fluvoxamine Maleate) in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placeb-controlled Study [NCT00353028]Phase 490 participants (Actual)Interventional2006-10-31Completed
Research Unit on Pediatric Psychopharmacology Anxiety Treatment Study [NCT00000389]Phase 30 participants Interventional1996-10-31Completed
Research on Standardized Electronic Cognitive Training Technique in Early Stage of Senile Depression With Cognitive Impairment [NCT05588102]128 participants (Anticipated)Interventional2021-05-18Recruiting
A Randomized Controlled Trial of Sertraline Combined With Fluvoxamine in the Treatment of Refractory Obsessive-compulsive Disorder [NCT04963257]Phase 4400 participants (Anticipated)Interventional2020-01-01Recruiting
A Baseline Controlled Study With Fluvoxamine to Evaluate the Effect on Polysonogram in Depressed Patients With Insomnia [NCT02442713]30 participants (Anticipated)Interventional2014-11-30Recruiting
A Phase I, Open-label, Non-randomised Study to Assess the Effect of Fluvoxamine (CYP1A2 Inhibitor) and Smoking (CYP1A2 Inducer) on the Pharmacokinetics of a Single Oral Dosing of AZD4635 in Healthy Volunteers [NCT04478513]Phase 128 participants (Actual)Interventional2020-07-21Completed
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial. [NCT05737511]Phase 480 participants (Anticipated)Interventional2023-12-30Not yet recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
FLUVOXAMINE AS A TREATMENT FOR LONG COVID-19: A RANDOMIZED PLACEBO CONTROLLED TRIAL [NCT05874037]Phase 2/Phase 3300 participants (Anticipated)Interventional2023-05-15Recruiting
A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder [NCT01933919]Phase 338 participants (Actual)Interventional2013-08-14Completed
A Phase 1, Open-Label, 4-Part Study to Evaluate the Effect of Food, Cytochrome P 450 Inhibition and Induction on the Pharmacokinetics of CC 122 in Healthy Adult Subjects [NCT03340662]Phase 181 participants (Actual)Interventional2017-11-09Completed
A Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD [NCT04539951]Phase 21,600 participants (Anticipated)Interventional2020-09-22Recruiting
A Phase 1, Fixed-Sequence, Open-Label Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP1A2 Inhibitor), Cigarette Smoking (CYP1A2 Inducer) and Itraconazole (CYP3A4 Inhibitor) on the Pharmacokinetics of TD-9855 in Healthy Subjects [NCT03432793]Phase 141 participants (Actual)Interventional2018-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00074815 (1) [back to overview]Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
NCT01933919 (12) [back to overview]Mean Change From Baseline in the JCY-BOCS 10-item Total Score at the End of Treatment in the First Phase Stratified by Gender
NCT01933919 (12) [back to overview]Mean Change From Baseline in the JCY-BOCS 10-item Total Score at the End of Treatment in the First Phase Stratified by Age
NCT01933919 (12) [back to overview]Mean Change From Baseline in the Japanese Children's Yale-Brown Obsessive Compulsive Scale 10-item Total Score at the End of Treatment in the First Phase
NCT01933919 (12) [back to overview]Percentage of Participants Much Improved in Clinical Global Impression Improvement Assessment During the Second Phase
NCT01933919 (12) [back to overview]Mean Change From Baseline in the JCY-BOCS 10-item Total Score at Each Visit During the First Phase
NCT01933919 (12) [back to overview]Percentage of Participants Much Improved in Clinical Global Impression Improvement Assessment During the First Phase
NCT01933919 (12) [back to overview]Number of Participants With Adverse Events During the Second Phase
NCT01933919 (12) [back to overview]Number of Participants With Adverse Events During the First Phase
NCT01933919 (12) [back to overview]Mean Change From Baseline in the JCY-BOCS 10-item Total Score at Each Visit During the Second Phase
NCT01933919 (12) [back to overview]JCY-BOCS 10-item Total Score at Each Visit During the First Phase
NCT01933919 (12) [back to overview]Percentage of Participants With a ≥ 35% Decrease From Baseline in JCY-BOCS (10-item) Total Score at the End of Treatment in the First Phase
NCT01933919 (12) [back to overview]Percentage of Participants With a ≥ 25% Decrease From Baseline in JCY-BOCS (10-item) Total Score at the End of Treatment in the First Phase
NCT02655354 (13) [back to overview]Number of Participants With Suicidal Ideation
NCT02655354 (13) [back to overview]SF-36 Quality of Life
NCT02655354 (13) [back to overview]TSOS Patient Satisfaction: Mental Health Care
NCT02655354 (13) [back to overview]TSOS Patient Satisfaction: Overall Health Care
NCT02655354 (13) [back to overview]Brief Pain Inventory
NCT02655354 (13) [back to overview]Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]Cognitive Impairment Scale
NCT02655354 (13) [back to overview]Number of Participants Endorsing a Single Item That Assesses Marijuana Use
NCT02655354 (13) [back to overview]Number of Participants Endorsing a Single Item That Assesses Opioid Use
NCT02655354 (13) [back to overview]Number of Participants Endorsing a Single Item That Assesses Stimulant Use
NCT04342663 (1) [back to overview]Number of Participants Who Met Clinical Worsening
NCT04510194 (4) [back to overview]Count of Participants Who Died
NCT04510194 (4) [back to overview]Count of Participants With ED Visit, Hospitalization or Death
NCT04510194 (4) [back to overview]Count of Participants With Hospitalization or Death
NCT04510194 (4) [back to overview]Count of Participants With Hypoxia Only
NCT04668950 (1) [back to overview]Number of Participants With Clinical Deterioration
NCT05890586 (14) [back to overview]Mean Days Benefit as Measured by the Symptom and Clinical Event Scale
NCT05890586 (14) [back to overview]Number of Participants With Hospitalization or Death
NCT05890586 (14) [back to overview]Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death
NCT05890586 (14) [back to overview]Quality of Life (QOL) as Measured by the PROMIS-29 - Social
NCT05890586 (14) [back to overview]Quality of Life (QOL) as Measured by the PROMIS-29 - Sleep
NCT05890586 (14) [back to overview]Quality of Life (QOL) as Measured by the PROMIS-29 - Physical Function
NCT05890586 (14) [back to overview]Quality of Life (QOL) as Measured by the PROMIS-29 - Pain
NCT05890586 (14) [back to overview]Quality of Life (QOL) as Measured by the PROMIS-29 - Fatigue
NCT05890586 (14) [back to overview]Time to Mortality
NCT05890586 (14) [back to overview]Quality of Life (QOL) as Measured by the PROMIS-29 - Depression
NCT05890586 (14) [back to overview]Quality of Life (QOL) as Measured by the PROMIS-29 - Anxiety
NCT05890586 (14) [back to overview]Time Unwell in Days as Measured by the Symptom and Clinical Event Scale
NCT05890586 (14) [back to overview]Time to Sustained Recovery in Days
NCT05890586 (14) [back to overview]Number of Participants With Mortality

Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

"OCD symptom severity was measured using the CY-BOCS, an interviewer-rated instrument that assess obsessions and compulsions separately on time consumed, distress, interference, degree of resistance, and control; it yields separate severity scores for obsessions and for compulsions (0 - 20), and a composite symptom severity score (0 to 40).~Consistent with signal detection analyses examining the optimal criterion for treatment response, a CY-BOCS reduction of 30% or more from baseline to week 12 was used as the criterion for RESPONSE and was the primary dichotomous outcome measure." (NCT00074815)
Timeframe: Measured at baseline and Week 12.

InterventionProportion of Participants with RESPONSE (Number)
MM + CBT0.69
MM + ICBT0.34
MM Only0.30

[back to top]

Mean Change From Baseline in the JCY-BOCS 10-item Total Score at the End of Treatment in the First Phase Stratified by Gender

The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions are rated on a scale from 0 (none) to 4 (extreme). The total score is calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms. (NCT01933919)
Timeframe: Baseline and week 10

Interventionunits on a scale (Mean)
Fluvoxamine - Males-11.9
Placebo - Males-7.0
Fluvoxamine - Females-9.3
Placebo - Females-6.0

[back to top]

Mean Change From Baseline in the JCY-BOCS 10-item Total Score at the End of Treatment in the First Phase Stratified by Age

The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions are rated on a scale from 0 (none) to 4 (extreme). The total score is calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms. (NCT01933919)
Timeframe: Baseline and week 10

Interventionunits on a scale (Mean)
Fluvoxamine - Ages 6-11-12.5
Placebo - Ages 6-11-10.3
Fluvoxamine - Ages 12-18-10.0
Placebo - Ages 12-18-5.6

[back to top]

Mean Change From Baseline in the Japanese Children's Yale-Brown Obsessive Compulsive Scale 10-item Total Score at the End of Treatment in the First Phase

The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of obsessive compulsive disorder (OCD) in the past 7 days. Severity of compulsions and obsessions are rated on a scale from 0 (none) to 4 (extreme). The total score is calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms. (NCT01933919)
Timeframe: Baseline and week 10

Interventionunits on a scale (Mean)
Fluvoxamine-10.5
Placebo-6.6

[back to top]

Percentage of Participants Much Improved in Clinical Global Impression Improvement Assessment During the Second Phase

"The investigator evaluated Clinical Global Impression (CGI) to rate participants' clinical symptomatology according to the following seven categories at each visit compared to the day of the first dose of study medication in the 2nd phase:~Very much improved~Much improved~Minimally improved~No change~Minimally worse~Worse~Very much worse~Much improved includes CGI score categories 'very much improved' and 'much improved'." (NCT01933919)
Timeframe: Baseline of the 2nd phase and weeks 1, 2, 3, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

,
Interventionpercentage of participants (Number)
Week 1Week 2Week 3Week 4Week 5Week 6Week 8Week 12Week 16Week 20Week 24Week 28Week 32Week 36Week 40Week 44Week 48Week 52Last post-baseline visit
Fluvoxamine/Fluvoxamine22.25.612.516.723.522.233.329.435.750.042.964.357.150.061.550.050.057.142.1
Placebo/Fluvoxamine7.120.035.733.354.546.760.053.364.364.353.858.340.027.325.045.527.336.446.7

[back to top]

Mean Change From Baseline in the JCY-BOCS 10-item Total Score at Each Visit During the First Phase

The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions are rated on a scale from 0 (none) to 4 (extreme). The total score is calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms. (NCT01933919)
Timeframe: Baseline and weeks 2, 4, 6, 8 and 10

,
Interventionunits on a scale (Mean)
Week 2Week 4Week 6Week 8Week 10
Fluvoxamine-3.9-5.1-8.8-8.6-10.8
Placebo-1.6-3.2-5.6-7.9-7.2

[back to top]

Percentage of Participants Much Improved in Clinical Global Impression Improvement Assessment During the First Phase

"The investigator evaluated Clinical Global Impression (CGI) to rate participants' clinical symptomatology according to the following seven categories at each visit compared to the day of the first dose of study medication:~Very much improved~Much improved~Minimally improved~No change~Minimally worse~Worse~Very much worse~Much improved includes CGI score categories 'very much improved' and 'much improved'." (NCT01933919)
Timeframe: Weeks 1, 2, 3, 4, 5, 6, 8, and 10

,
Interventionpercentage of participants (Number)
Week 1Week 2Week 3Week 4Week 5Week 6Week 8Week 10Last post-baseline visit
Fluvoxamine0.05.35.310.526.338.942.150.052.6
Placebo0.00.011.15.95.929.443.843.838.9

[back to top]

Number of Participants With Adverse Events During the Second Phase

"An adverse event was assessed as treatment-related by the investigator if there was evidence to suggest a causal relationship between the study drug and the adverse event.~The investigator used the following definitions to rate the severity of each adverse event:~Mild: The adverse event was transient and easily tolerated by the participant;~Moderate: The adverse event caused the participant discomfort and interrupted usual activities.~Severe: The adverse event caused considerable interference with the participant's usual activities and may have been incapacitating or life-threatening.~A serious adverse event was any event that resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, congenital anomaly, persistent or significant disability/incapacity, or was an important medical event requiring medical or surgical intervention to prevent a serious outcome." (NCT01933919)
Timeframe: From the first dose of the study drug up to 30 days after the last dose of the study drug, approximately 60 weeks in the second phase of the study.

,
Interventionparticipants (Number)
Any adverse eventTreatment-related adverse eventSevere adverse eventSerious adverse eventAE leading to discontinuation of study drugAE leading to death
Fluvoxamine/Fluvoxamine1570020
Placebo/Fluvoxamine1570100

[back to top]

Number of Participants With Adverse Events During the First Phase

"An adverse event (AE) was assessed as treatment-related by the investigator if there was evidence to suggest a causal relationship between the study drug and the adverse event.~The investigator used the following definitions to rate the severity of each adverse event:~Mild: The adverse event was transient and easily tolerated by the participant;~Moderate: The adverse event caused the participant discomfort and interrupted usual activities.~Severe: The adverse event caused considerable interference with the participant's usual activities and may have been incapacitating or life-threatening.~A serious adverse event was any event that resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, congenital anomaly, persistent or significant disability/incapacity, or was an important medical event requiring medical or surgical intervention to prevent a serious outcome." (NCT01933919)
Timeframe: From the first dose of the study drug up to 30 days after the last dose of the study drug, approximately 18 weeks in the first phase.

,
Interventionparticipants (Number)
Any adverse eventTreatment-related adverse eventSevere adverse eventSerious adverse eventsAE leading to discontinuation of study drugAE leading to death
Fluvoxamine1360000
Placebo1550010

[back to top]

Mean Change From Baseline in the JCY-BOCS 10-item Total Score at Each Visit During the Second Phase

"The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions are rated on a scale from 0 (none) to 4 (extreme). The total score is calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms.~Baseline for the 2nd phase was the first visit of the 2nd phase after completion of the tapering period in the first phase and prior to study drug administration in the 2nd phase." (NCT01933919)
Timeframe: Baseline of the 2nd phase and weeks 2, 8, 16, 28, 40, and 52 of the 2nd phase

,
Interventionunits on a scale (Mean)
Baseline of 2nd phaseChange from baseline at week 2Change from baseline at week 8Change from baseline at week 16Change from baseline at week 28Change from baseline at week 40Change from baseline at week 52Change from baseline at last post-baseline visit
Fluvoxamine/Fluvoxamine14.8-0.2-1.2-1.3-0.7-1.9-3.1-1.7
Placebo/Fluvoxamine20.4-1.1-4.3-7.1-6.2-5.6-6.6-8.1

[back to top]

JCY-BOCS 10-item Total Score at Each Visit During the First Phase

The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions are rated on a scale from 0 (none) to 4 (extreme). The total score is calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms. (NCT01933919)
Timeframe: Baseline and weeks 2, 4, 6, 8 and 10

,
Interventionunits on a scale (Mean)
BaselineWeek 2Week 4Week 6Week 8Week 10Last post-baseline visit
Fluvoxamine26.622.721.517.417.915.416.1
Placebo27.325.124.222.119.620.720.7

[back to top]

Percentage of Participants With a ≥ 35% Decrease From Baseline in JCY-BOCS (10-item) Total Score at the End of Treatment in the First Phase

The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions were rated on a scale from 0 (none) to 4 (extreme). The total score was calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms. (NCT01933919)
Timeframe: Baseline and week 10

Interventionpercentage of participants (Number)
Fluvoxamine68.4
Placebo33.3

[back to top]

Percentage of Participants With a ≥ 25% Decrease From Baseline in JCY-BOCS (10-item) Total Score at the End of Treatment in the First Phase

The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions were rated on a scale from 0 (none) to 4 (extreme). The total score was calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms. (NCT01933919)
Timeframe: Baseline and week 10

Interventionpercentage of participants (Number)
Fluvoxamine73.7
Placebo44.4

[back to top]

Number of Participants With Suicidal Ideation

Item 9 of the Patient Health Questionnaire 9-item (PHQ-9) scale assesses suicidal ideation. It is scored from 0 to 3, with a score of 1 or greater indicating a patient has suicidal ideation. Participants with a PHQ-9 item 9 score of greater than or equal to 1 are reported for this outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention67696351
Usual Care909910692

[back to top]

SF-36 Quality of Life

The SF-36 assess quality of life domains that span emotional health, overall health status, and role function; a score of 100 indicates perfect health and a score of 0 indicates extremely poor health. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention44.338.338.439.2
Usual Care45.139.139.541.4

[back to top]

TSOS Patient Satisfaction: Mental Health Care

Satisfaction with mental health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied. (NCT02655354)
Timeframe: Baseline, 3 Month, 6 Month, 12 Month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention4.13.63.63.7
Usual Care4.03.53.43.5

[back to top]

TSOS Patient Satisfaction: Overall Health Care

Satisfaction with health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention4.43.94.03.9
Usual Care4.43.83.83.8

[back to top]

Brief Pain Inventory

A brief measure scored on a 0 to 10 scale to assess a patient's pain, with a higher score indicating more severe pain; a score of 0 indicates no pain and a score of 10 indicates very severe pain. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention6.84.34.13.9
Usual Care6.74.74.53.8

[back to top]

Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury

The investigators will use the Alcohol Use Disorders Identification Test (AUDIT) as a continuous measure. The 10-item scale score ranges from 0-40, with higher values indicating a worse outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-2.04-1.69-1.81
Usual Care-1.90-1.63-1.45

[back to top]

Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury

The investigators will use the Patient Health Questionnaire 9-item Depression Scale (PHQ-9). The scoring of the scale ranges from a minimum of 0 to a maximum of 27, with higher scores indicating a worse outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-0.79-1.17-1.84
Usual Care-0.50-0.90-2.16

[back to top]

Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury

The investigators will use the PTSD Checklist - Civilian (PCL-C). The scoring of the scale ranges from a minimum of 17 to a maximum of 85, with higher scores indicating a worse outcome. The measure can also provide a rating of symptoms consistent with a diagnosis of PTSD. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-1.65-4.02-5.51
Usual Care0.08-1.44-4.25

[back to top]

Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury

The investigators used the Medical Outcomes Study Short Form healthy survey (MOS SF-12/36) physical components summary to assess physical function. The minimum and maximum scores are 0-100 with higher scores representing a better outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-16.78-14.17-13.23
Usual Care-15.90-13.83-11.68

[back to top]

Cognitive Impairment Scale

The investigators will use the National Study on the Costs and Outcomes of Trauma (NSCOT) Cognitive Screen, a 4 - Item Traumatic Brain Injury / Post-concussive Symptom Screen. The scoring of the scale ranges from a minimum of 4 to a maximum of 20, with lower scores indicating a worse outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention13.513.313.213.8
Usual Care13.413.213.414.2

[back to top]

Number of Participants Endorsing a Single Item That Assesses Marijuana Use

Single items that assess marijuana use. Single item self-report dichotomized as none versus at least monthly use. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention125606051
Usual Care177728279

[back to top]

Number of Participants Endorsing a Single Item That Assesses Opioid Use

Single items that assess non-prescribed opioid use. Single item self-report dichotomized as none versus at least monthly use. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention18446
Usual Care4415206

[back to top]

Number of Participants Endorsing a Single Item That Assesses Stimulant Use

Single items that assess non-prescribed stimulant use. Single item self-report dichotomized as none versus at least monthly use. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention58978
Usual Care77172216

[back to top]

Number of Participants Who Met Clinical Worsening

Clinical worsening is defined meeting both of the following: (1) presence of dyspnea and/or hospitalization for shortness of breath or pneumonia, plus (2) decrease in O2 saturation (<92%) on room air and/or supplemental oxygen requirement in order to keep O2 saturation >92%. (NCT04342663)
Timeframe: RCT (approximately 15 days)

InterventionParticipants (Count of Participants)
Fluvoxamine0
Placebo6

[back to top]

Count of Participants Who Died

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group0
Treatment Arm - Placebo Group0
Treatment Arm - Ivermectin Only Group0
Treatment Arm - Fluvoxamine Only Group0
Treatment Arm - Metformin and Fluvoxamine Group0
Treatment Arm - Metformin and Ivermectin Group1

[back to top]

Count of Participants With ED Visit, Hospitalization or Death

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group27
Treatment Arm - Placebo Group48
Treatment Arm - Ivermectin Only Group16
Treatment Arm - Fluvoxamine Only Group15
Treatment Arm - Metformin and Fluvoxamine Group18
Treatment Arm - Metformin and Ivermectin Group23

[back to top]

Count of Participants With Hospitalization or Death

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group8
Treatment Arm - Placebo Group18
Treatment Arm - Ivermectin Only Group5
Treatment Arm - Fluvoxamine Only Group5
Treatment Arm - Metformin and Fluvoxamine Group6
Treatment Arm - Metformin and Ivermectin Group4

[back to top]

Count of Participants With Hypoxia Only

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group147
Treatment Arm - Placebo Group158
Treatment Arm - Ivermectin Only Group88
Treatment Arm - Fluvoxamine Only Group73
Treatment Arm - Metformin and Fluvoxamine Group71
Treatment Arm - Metformin and Ivermectin Group96

[back to top]

Number of Participants With Clinical Deterioration

Defined as the number of participants who experienced the following: both of the following: 1)Presence of dyspnea and/or hospitalization for shortness of breath or pneumonia, 2)) decrease in O2 saturation (<92% on room air) and/or supplemental oxygen requirement to keep O2 saturation ≥92%). (NCT04668950)
Timeframe: RCT-approximately 15 days

InterventionParticipants (Count of Participants)
Fluvoxamine13
Placebo15

[back to top]

Mean Days Benefit as Measured by the Symptom and Clinical Event Scale

The symptom and clinical event scale is a daily measurement that combines the global symptom burden scale with clinical events hospitalization and mortality. (No symptoms, mild symptoms, moderate symptoms, severe symptoms, hospitalized, deceased). The cumulative benefit of treatment A is the probability of experiencing a better outcome on treatment A compared to treatment B, summed over the days of follow-up. The difference between the cumulative benefit of treatment A and the cumulative benefit of treatment B is known as the difference in days benefit. Measure of dispersion is 95% credible interval. (NCT05890586)
Timeframe: Up to 14 days

Interventiondays (Mean)
Arm B - Fluvoxamine 503.45
Arm B - Placebo3.37

[back to top]

Number of Participants With Hospitalization or Death

(NCT05890586)
Timeframe: Up to 28 days

InterventionParticipants (Count of Participants)
Arm B - Fluvoxamine 501
Arm B - Placebo3

[back to top]

Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death

(NCT05890586)
Timeframe: Up to 28 days

InterventionParticipants (Count of Participants)
Arm B - Fluvoxamine 5027
Arm B - Placebo26

[back to top]

Quality of Life (QOL) as Measured by the PROMIS-29 - Social

The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20 where a higher score correlates to better outcome for social roles and activities. Day 90 data to be reported by September 4, 2023. (NCT05890586)
Timeframe: Day 7, 14, 28, and 90

,
Interventionscore on a scale (Median)
Day 7Day 14Day 28Day 90
Arm B - Fluvoxamine 5016.5202020
Arm B - Placebo18202020

[back to top]

Quality of Life (QOL) as Measured by the PROMIS-29 - Sleep

The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20 where a lower score correlates to better outcome for sleep. Day 90 data to be reported by September 4, 2023. (NCT05890586)
Timeframe: Day 7, 14, 28, and 90

,
Interventionscore on a scale (Median)
Day 7Day 14Day 28Day 90
Arm B - Fluvoxamine 5010988
Arm B - Placebo10988

[back to top]

Quality of Life (QOL) as Measured by the PROMIS-29 - Physical Function

The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20, where a higher score correlates to better outcome for physical function. Day 90 data to be reported by September 4, 2023. (NCT05890586)
Timeframe: Day 7, 14, 28, and 90

,
Interventionscore on a scale (Median)
Day 7Day 14Day 28Day 90
Arm B - Fluvoxamine 5020202020
Arm B - Placebo20202020

[back to top]

Quality of Life (QOL) as Measured by the PROMIS-29 - Pain

The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20, where a lower score correlates to better outcome for pain. Day 90 data to be reported by September 4, 2023. (NCT05890586)
Timeframe: Day 7, 14, 28, and 90

,
Interventionscore on a scale (Median)
Day 7Day 14Day 28Day 90
Arm B - Fluvoxamine 504444
Arm B - Placebo4444

[back to top]

Quality of Life (QOL) as Measured by the PROMIS-29 - Fatigue

The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20, where a lower score correlates to better outcome for fatigue. Day 90 data to be reported by September 4, 2023. (NCT05890586)
Timeframe: Day 7, 14, 28, and 90

,
Interventionscore on a scale (Median)
Day 7Day 14Day 28Day 90
Arm B - Fluvoxamine 50874.54
Arm B - Placebo8744

[back to top]

Time to Mortality

Time to mortality was the number of days between drug receipt and death. (NCT05890586)
Timeframe: Up to 28 days

Interventiondays (Mean)
Arm B - Fluvoxamine 50NA
Arm B - PlaceboNA

[back to top]

Quality of Life (QOL) as Measured by the PROMIS-29 - Depression

The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20, where a lower score correlates to better outcome for depression. Day 90 data to be reported by September 4, 2023. (NCT05890586)
Timeframe: Day 7, 14, 28, and 90

,
Interventionscore on a scale (Median)
Day 7Day 14Day 28Day 90
Arm B - Fluvoxamine 504444
Arm B - Placebo4444

[back to top]

Quality of Life (QOL) as Measured by the PROMIS-29 - Anxiety

The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20 where a lower score correlates to better outcome for anxiety. (NCT05890586)
Timeframe: Day 7, 14, 28, and 90

,
Interventionscore on a scale (Median)
Day 7Day 14Day 28Day 90
Arm B - Fluvoxamine 505444
Arm B - Placebo5444

[back to top]

Time Unwell in Days as Measured by the Symptom and Clinical Event Scale

The symptom and clinical event scale is a daily measurement that combines the global symptom burden scale with clinical events hospitalization and mortality. (No symptoms, mild symptoms, moderate symptoms, severe symptoms, hospitalized, deceased). Time unwell was the portion of follow-up (in days) that a participant was symptomatic, hospitalized, or deceased. The quantity is estimated from a Bayesian longitudinal ordinal regression model with covariate adjustment and weakly informative priors. (NCT05890586)
Timeframe: Up to 14 days

Interventiondays (Mean)
Arm B - Fluvoxamine 5011.21
Arm B - Placebo11.28

[back to top]

Time to Sustained Recovery in Days

Time to sustained recovery was the number of days between receipt of study drug and the third of 3 consecutive days without symptoms. Participants who died, by definition, did not recover regardless of reported symptom freedom. The reported summary is the median survival time. (NCT05890586)
Timeframe: Up to 28 days

Interventiondays (Median)
Arm B - Fluvoxamine 5012
Arm B - Placebo13

[back to top]

Number of Participants With Mortality

(NCT05890586)
Timeframe: Up to 28 days

InterventionParticipants (Count of Participants)
Arm B - Fluvoxamine 500
Arm B - Placebo0

[back to top]